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AIM OF THE STUDY
Purpose of the Project 
 Study of C reactive protein level in obese person with BMI of
more than 25 kg/m2.
Objective
To test whether overweight and obesity are associated with low-
grade systemic inflammation as measured by serum C-reactive protein 
(CRP) level.  
To study the c reactive protein level in obesity using measures of 
body mass index. 
To study CRP level in obese women and men.
Data Collection and the Source
Patient attending OPD ward is examined BMI. Body weight and
height were measured using standardized procedures. Body mass index
(BMI) was calculated as weight in kilograms divided by the square of
height in meters and used as an indicator of body fat.
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ABBREVIATIONS
VPC Ventricular premature complexes 
APC  Atrial premature complexes
VT Ventricular tachycardia
ST Supraventricular tachycardia 1
OSA Obstructive Sleep Apnea 
OHS Obesity hypoventilation syndrome 
FFA Free fatty acids 
IGT Impaired glucose tolerance 
IR Insulin resistance 
DM Diabetes mellitus
GH Growth hormone 
MS Metabolic syndrome
SHT Systemic hypertension 
Bp Blood pressure
SHT System hyper tension A
IHD Ischemic heart disease
SCAT Subcutaneous adipose tissue
PCOD Poly cystic ovary disease
OA Osteoarthritis
Positive (HR) High Risk - >3ml/lr
Positive (MR) Moderate Risk- 1-3ml/lr
Negative Low risk - <1mg/lr
INTRODUCTION
INTRODUCTION
Obesity is nothing but, a chronic common disease characterized by
excess body fat. It develops gradually and often persists throughout life.
As a  preventable cause of  death in the US,  obesity is  second only to
smoking. Like other chronic condition, such as diabetes or hypertension,
obesity  worsens  when  strategies  applied  for  weight  reduction  are
withdrawn. If it is not treated, obesity emerges as a potent comorbid risk
factor. 
Nowadays obesity is emerging as an important health trouble in
India. About 22 million Indians are obese especially abdominally obese.
The nutrition foundation of India (NFI) study showed that 32.3 percent of
middle class males and 50 percent of middle class females in New Delhi
were  obese.  Overweight  and  obesity  are  escalating  in  Asian  Indians
especially those living in urban areas. Particularly vulnerable subgroups
include children, women, and people living in suburban and rural areas.
Body  composition  characteristic  of  Asian  Indians  (high  body  fat,
abdominal  adip17osity,  truncal  subcutaneous  fat,  and  fatty  liver)
predispose  them  to  develop  insulin  resistance  and  the  metabolic
syndrome early in life.
Obesity  carries  chronic  health  issues.  The  most  seriousness  of
obesity may be completely understood by – Epidemiologic transmission
theory. It traces the human history based on mortality.
I phase – femine and pestilence
II phase – receding pandemics
It is the later part of 19th and early years of 20th century. 
III phase – middle of 20th century
It is mortality by cancer
In this  phase death by cardiac  illness are decreasing because of
preventing medicine and advanced treatment.
IV phase – presenting era. Obesity and physical inactivity
 Previous improvement in cardiovascular mortality is worsened by
obesity hyperendemicity. 
Over  ten  years  97  million  people  are  in  the  classification  of
overweight and obesity. Nowadays it is over than 140 million. 
Obesity  influences  staggering  medical  management  and
economical lose. It increases the death rate in SHT, DM, and IHD.
Excess abdominal adiposity directly influences the SHT, DM, IR,
IHD and dyslipidemia.  It  is  directly  related  to  duration of  obesity.  In
obese population, marked increase in inflammatory markers released by
dysfunctional adipocytes. The main inflammatory markers are CRP, IL6,
TNFα. 
These  markers  predict  the  future  outcome  of  the  obese  people.
Maturation of preadipocyte to dysfunctional adipocyte was affected by
chronic energy imbalance. 
The  role  of  inflammation  in  atherosclerosis  proves  that
inflammatory  mediators  are  taking  part  in  endothelial  injury  plaque
formation  and  unstable  plaque.  When  the  stimulus  for  production  of
inflammatory  markers  (energy  imbalance  and  physical  inactivity)  are
stopped, inflammatory drops dramatically to the normal. 
In our study BMI was taken for obesity measurement and serum
CRP level is used to measure the severity of the obesity. 
REVIEW OF LITERATURE
DEFINITION
It is a state of excess adipose tissue mass 1. Body weights are 
distributed continuously in human population. Medically definite 
difference between lean and obese is difficult. 
PREVALENCE
Around 1.2 billion people in the world are overweight and at least
300  million  of  them  are  affected  by  obese.  According  to  the  WHO,
obesity is one of the ten most preventable health risks. National health
and nutritional  examination services  (NHANES)  shows that  American
adult with obesity (BMI >30) increased 14.5 % to 33.9%. The prevalence
of obesity is more among poor and women, and blacks and Hispanics.
Incidence and prevalence also rising among childrens. 
SOCIETAL IMPACT
Obesity and its consequences increase economic costs of obesity
hospital2. Visits due to obesity increased by 88% from 1988 to 1994  3.
Hospital visit have been found to be 38% higher in obese population than
normal weight persons 4. Obesity has a major health and economic cost in
world.
MORTALITY RATES AND OBESITY 
Obesity  and  mortality  rates  depend  on the  following factors:  1.
smoking  2.  pre-existing  disease  and  weight  fluctuation  3.  Physical
inactivity 4. the lack of precision and accuracy in the use of BMI as an
estimate of adiposity 5. 
OBESITY MEASUREMENTS
Three anthropometric measures are used to evaluate the obesity.
They are weight, height, and waist circumference. 
Body mass index (BMI)
It is measured as weight in kg / height in m2, or weight in pounds /
height in inches2 X 703. It is helpful to grade and it risks. It is commonly
used indices in world wide. It gives and calculates approximately of body
fat and its risk. Lower BMI has been proposed for Asian pacific region
because these people at risk for glucose and lipid abnormalities in lower
BMI. 
Table 1. Classification of obesity with BMI level
BMI (kilogram/
meter2) Obesity Class Risk of Disease
Under weight <18.5
Healthy weight 18.5-24.9
Overweight 25.0-29.9 Increased
Obesity 30.0-34.9 I High
Obesity 35.0-39.9 II Very high
Extreme obesity ≥40 III Extremely high
BMI is lower for Asian Indians than western population.
Normal BMI : 18.0 – 22.9 kilogram/meter2
Overweight : 23.0 – 24.9 kilogram/meter2
Obesity : >25 kg/m2. 6,7
Ideal body weight (IBW)
Ideal body weight = 22.5 x height (meters2)
Over weight – > 10% of IBW
Underweight    - < 20% of IBW
Obesity – > 20% of IBW
Thickness of Skin-fold 
It  is  measured  by  special  pair  of  callipers  over  the  triceps,  biceps,
subscapular and suprailiac region.  
Normal triceps thickness of skin-fold 
Adult males- 12.5 mm
Adult females – 16.5 mm
Broca’s index
Height (inches) = weight (kg)
Height (cm) – 100 = desired body weight (kg)
Ratio of Waist-hip 
It is helpful to measure the prognosis of obesity. Waist measurement of
narrowest  segment  between  ribcage  and  iliac  crest.  Hip-maximal
measurement  of  the  hip  in  gluteal  region.  Apple-shaped  obesity  is
abdominal  obesity,  which  is  seen  with  type2  diabetesmelitus  and
ischaemic heart diseases, hyperlipidaemia and insulin resistance.
Waist to hip ratio Obesity type Prognosis
0.8 or < Pear-shaped obesity Good
0.9 or > Apple-shaped obesity poor
Circumference of Waist 
It is useful to consider the prediction in obese population.
Waist circumference and risk of morbidity 
Gender Moderate High
Male gender > 94 cm (37”) > 102 cm (40”)
Female gender > 80 cm (32”) > 88 cm (35”)
Other measure to quantify obesity include, 
 Densitometry (under water weighing)
 CT or MRI 
 Electrical impedance
 Dual energy X-ray Absorbtiometry (DEXA) is used to measure the
percentage of body fat. 
OBESITY PANDEMIC
Eating habits
Polices on production of food and the accessibility of high fat “fast
food” or high glycemic foods are factors that contribute to the prevalence
of obesity in society. The increase affordability for junk food leads to
high energy consumption. 
We need not to spend most of our time in hunting and gathering
food as our ancestors did; instead we can get the food any corner like fast
food stalls, restaurants. WHO recently reports that more mortality caused
by obesity and physical inactivity. This could be prevented by healthy
food and physical exercise8.
Sedentary lifestyle
A change in food production and marketing leads to physical inactivity.
Most of the jobs are sedentary 9. Physical inactivity is associated with a
risk  of  obesity  and obesity  and IHD  10.  Transport  by  walking is  now
replaced by vehicles. This is an important in sedentary lifestyle across all
over the world. England health survey in 1998 reported that 70-80 percent
of the persons lead sedentary live 11. 
Psychological stress
Part of life starting from school education to job or business stress
till  end  of  life.  Most  of  the  case  studies  shows  that  job  stress  and
cardiovascular disease (CVD) mortality among male  12.  Job stress also
leads to physical inactivity, eating behaviours that may be contributed to
BMI 13. 
SECONDARY OBESITY
Obesity  secondary  to  some  pathology  constitutes  a  minority  of
patients. This subset of patients includes various genetic syndromes like
prader  Willi  syndrome,  Lawrence  Moon  Biedl  Syndrome  etc.;
hypothalamic lesions; various endocrinopathies like Cushing’s syndrome,
Hypothyroidism etc; and drug induced. 
Homeostasis of body weight
Fig. 1 Homeostasis of body weight
Physiological  mechanism by which homeostasis  of  the  body fat
and energy stores are maintained. This mechanism is seen both in normal
and obese individuals. When body weight is lost due to calorie deficit,
homeostatic  mechanisms  come  into  play  that  results  in  restoration  of
weight  by  increasing  appetite  and  decreasing  energy  expenditure;  the
opposite  happens  when  body  weight  is  gained.  These  homeostatic
mechanisms act till the weight is brought to the ‘set-point weight’ or the
‘defended weight’ of the particular individual.
Body  weight  or  energy  homeostasis  occurs  between  the
hypothalamus,  adipose tissue,  gastrointestinal  tract,  liver,  pancreas and
the nervous system, more specifically the sympathetic nervous system.
Information about energy stores and energy needs is conveyed from the
periphery to the hypothalamus. 
The hypothalamus responds by sending signals resulting in hunger
and  energy  conservation  or  satiety  and  energy  expenditure,  as  the
situation  may  demand.  The  satiety  centre  is  located  in  the  medical
hypothalamus  and  includes  the  arcute  nucleus.  The  hunger  centre  is
present in the lateral hypothalamus. Lesions of the medial hypothalamus
cause  hyperphagia  and  obesity;  whereas  lesions  of  the  lateral
hypothalamus results in anorexia and cachexia.    
Leptin secreted from the adipose tissue acts as a gauge for energy
stores, with increased levels seen in obesity and decreased levels in seen
in  cachexia  14.  In  states  of  calorie  excess,  leptin  acts  on  the  leptin
receptors in hypothalamus to decreases appetite and to increase energy
expenditure via the POMC (pro-opiomelanocortin) neurons. 
The sympathetic  nervous system acts  via  the β3 receptor  in the
skeletal  muscles  and  brown  adipose  tissue,  resulting  in  non-shivering
(non-energy/adaptive) thermogenesis  15. Signals are also conveyed from
the gastrointestinal tract and the pancreas. Feeding and gastrointestinal
distension results in release of cholecystokinin, peptide YY, GLP-1 and
insulin  which  decrease  appetite;  whereas  when  energy  stores  are  low
ghrelin is released from the stomach resulting in increased appetite 16-18. 
Sex  steroids  also  contribute  to  this  homeostasis,  with  estrogen
favoring subcutaneous fat accumulation and androgens favoring central
fat  accumulation  19.  This  homeostatic  mechanism  of  energy  storage
maybe modulated in certain conditions like fever, where cytokines acting
on the hypothalamus may cause anorexia.
Fig. 2. Leptin and its regulated mechanism
OTHER HORMONES INVOLVED IN OBESITY
Neuropeptide Y (N-Y)
Leptin  function and  its  effects  on energy  intake are  the  role  of
neuropeptide Y 20. For food intake N-Y is the important stimulator. It is
related to leptin dysfunction and enegy imbalance. Increase level of N-Y
seen in SHT and DM who are obese 21. 
Cortisol
It  has very high metabolic action. It  mobilizes FFA from stored
TGL and takes part in glucose synthesis from amino acids and fat and has
role in protein metabolism 22. In Cushing disease people increase level of
Cortisol is seen and it contribute visceral and abdominal adipocytes 23,24.
Ghrelin 
I  t  is  a  GH  secretagogue  mainly  present  in  stomach;  it  was
stimulated  by  fasting  state  and  inhibited  by  feeding.  The  effect  was
controlled by central inhibition of leptin and other cytokines. The signal
is  transmitted  by  a  neural  pathway  (vagus).  It  also  mediated  by
hypothalamic N-Y. It also take part in GH regulation 25-27 . 
Norepinephrine (NE), Serotonin, Interleukin-6 and TNFα 
These factors have shown to have influence on energy intake and
contribute to weight gain. NE increases and decreases the food intake by
acting on specific receptor. if it acts on alpha-1 receptors in the PVN it
inhibits food intake. In contrast, when NE acts on alpha-2 receptors in the
PVN it inhibits food intake. 
Serotonin action also in same fashion.  It acts on the 5HT1A and 5-
HT2C receptor 28. Action on 5HT1A stimulates, and 5-HT2C  action inhibits
food intake.  IL-6 is a inflammatory marker highly associated with high
level  of  BMI.  It  modulate  lipid metabolism in  adipose tissue  29.  TNF
alpha  stimulate  IL-6  synthesis  from  adipose  tissue  P80  receptors  of
adipose tissue. It also an inflammatory markers. 
Testosterone 
Testosterone decreases the LPL activity and stimulates lipolysis in
men,  in  females  it  was  overcome  by  female  sexsteroid  like  estrogen.
Testosterone influence s the leptin mRNA 30. 
The growth hormone/insulin like growth factor axis .it is one of
the  regulatory  mechanisms.  It  is  take  parts  in  lipid  metabolism  and
synthesis  of  protein  and  prevent  proteolysis  by  IGF-1.  thyrotropin
stimulating hormone (TSH)  has main  action on BMI and obesity 33.
TSH and  BMI  were positively  related  and  TSH level  correlated  with
leptin level.
Fig.  3. The factors regulating food intake and energy expenditure
Fig. 4. Leptin action in various pathways
BASIC PATHOLOGY IN OBESITY
1. Hypothalamic dysfunction
2. Adipose tissue dysfunction
3. Alterations in gut signals-role of gut microbiome
4. Ineffectiveness of adaptive thermogenesis
Fig. 5. Physiological dysregulation in obesity
1. Hypothalamic dysfunction
Hypothalamic  dysfunction  can  result  in  loss  of  homeostasis
resulting in cachexia or obesity. Experimental studies in mice have shown
that  high  fat  diet  results  in  hypothalamic  inflammation  34.  This
inflammation results in the destruction of the POMC neurons and induces
leptin resistance in the hypothalamus. 
Janus  kinase-signal  was  play  role  in  Leptin  signalling  and
transcription pathway activation was inhibited by inflammation. It results
in  leptin  resistance.  So  there  is  increasing  body  weight  that  leads  to
elevation  in  ‘set-point-weight’  35.  These  change  in  the  difficulty  in
maintaining weight following a weight loss program. 
Leptin decreases appetite by a number of mechanisms like direct action
on  the  hypothalamus,  increased  POMC  activity,  increased  GLP-1
secretion from the gut and increasing activity in the nucleus accumbens. 
The nucleus acumens are described mainly in the context of drug
addiction, where it acts as a ‘reward’ centre. Food intake can stimulate
the nucleus accumbenes resulting in a sense of satiety (‘reward’). This is
known as  the hedonic value of food. With leptin this sense of reward
occurs  even  without  food  intake.  Thus  in  leptin  resistance  of  obesity
satiety does not occur.
2. Adipose tissue dysfunction
Adipose tissue dysfunction causes not only the complications of
obesity but may have a role in the pathogenesis of obesity. The adipose
tissue inflammation arising out of adipose tissue hypoxia. Hypoxia occurs
due to the expanding adipose tissue mass, as a result the adipose tissue is
stripped of its vascular supply since the capillaries are unable to perfuse
to such a large extent. 
Hypoxia results in inflammation and the inflammatory cytokines result
in macrophage infiltration and further inflammation 36. The inflammation
can  cause  leptin  resistance  and  the  resultant  increase  in  weight.  The
inflamed  adipose  tissue  is  dysfunctional  and  insulin  resistant  with
increased release of adiponection. Adiponection is anti-inflammatory and
is protective against atherosclerotic cardiovascular disease.
3. Role of gut microbiome
.
Fig.6  Role of gut microbiota
The  revised  view  of  adipose  tissue  inflammation,  the  gut
microbiota has been implicated. The symbiotic gut microorganisms in the
human intestine (the microbiome) are a metabolically active organ that is
now known to have a pathogenetic role in obesity. Germ free mice are
known to be resistant to diet induced obesity, insulin resistance and diet
induced obesity. 
FIAF  is  suppressed  in  the  gut  mucosa  by  the  microbiota.  Gut
microbiota promotes the lipoprotein lipase activity with increased uptake
of FFA. Gut microbiota can also affect the secretion of gut hormones like
peptide YY and GLP-1, thereby affecting gut transit time, energy harvest
and  satiety  37.  The  gut  microbiome  increases  the  efficiency  of  fat
absorption, decreases fat oxidation and interferes with the signalling of
the satiety hormones from the gut.
Adipocytes, macrophages and cells of the adaptive immunity like T
lymphocytes for producing adipose tissue inflammation. T lymphocytes
first  infiltrate  the adipose tissue.  The infiltrating T lymphocytes  (TH1)
result in the phenotypic switch of macrophages in the adipose tissue, from
the  anti-inflammatory  M2  macrophages  to  the  pro-inflammatory  M1
macrophages via the release of IFN γ and IL-17 from the T lymphocytes. 
High fat diet results in temporary damage to the intestinal villi and
increases  the  capillary density  resulting in  the increased absorption of
antigens from the gut which can be inflammatory. The gut microbiome is
known  to  be  increased  in  obesity.  The  lippolysaccharide  of  the  gut
bacteria is thus absorbed along with fat and gains access to the adipose
tissue via chylomicrons, and thus inflammation is initiated in the adipose
tissue 38.
IMPAIRMENT OF ADAPTIVE THERMOGENESIS
Hypothalamus controls  energy expenditure  is  via  the  sympathetic
nervous system where adaptive thermogenesis results in the dissipation of
energy as  heat  rather  than being stored.  This  is  brought  about  by the
uncoupling protein 1 in the inner mitochondrial membrane of the brown
adipose tissue (BAT).
 Brown  adipose  tissue  developed  as  a  protective  mechanism for
adaptive thermogenis. But, the use of PET scanning for the detection of
malignancy changed this belief. During PET imaging, BAT was found in
the supraclavicular, infrascapular, cervical, regions and also around the
great vessels and adrenals. 
Brown  and  white  adipocytes,  mytocytes,  osteoblasts  and
chondrocytes all develop from the mesenchymal stem cell (MSC). BAT
and  white  adipose  tissue  (WAT)  are  morphologically  different.  BAT
adipocytes  are  smaller,  polygonal,  have  a  central  nucleus  and  have
multiple lipid droplets. 
They have a brownish hue to the rich mitochondrial content (the
mitochondrial  content  is  comparable  to  the  cardiac  myocytes).  The
abundance of mitochondria which contains respiratory chain cytochrome
enzymes  with  iron as  a  co-factor  gives  it  a  brown appearance.  White
adipocytes  are  rounded,  larger  with  a  single  lipid  droplet,  have  a
peripherally located nucleus and have low mitochondrial content. 
Recent evidence shows that the expression of Myf5 gene in brown
adipocytes mean that they share a common lineage with myocytes rather
than with adipocytes. PGC1α increases the synthesis of UCP1 in the BAT
by stimulating its promoter. Increased release of irisin from the skeletal
muscle during exercise results in the browning of the white adipocytes,
making them ‘beige’ or ‘brite’. 
This may be one of the mechanisms how exercise causes weight
loss  and  improved  insulin  resistance.  Another  transcriptional  factor
FGF21 has been implicated in the browning of the white adipose tissue 39.
Fig. 7. White adipose tissue and its effects
NATRIURETIC PEPTIDES AND ADAPTIVE THERMOGENESIS
Natriuretic peptides are increased in heart failure; in fact they seem
to play a role in the pathogenesis of cardiac cachexia. Natriuretic peptides
cause  natriuresis  and  dieresis,  decrease  preload  and  afterload  in  heart
failure. Natriuretic peptides have been found to cause lipolysis, fatty acid
oxidation  and  browning  of  the  white  adipose  tissue.  In  obesity,  the
natriuretic  peptide  level  is  low.  This  has  been  proposed  to  be  due  to
increased natriuretic peptide clearance receptor in the adipose tissue. 
Natriuretic  peptides  also  increase  mitochondrial  oxidative
metabolism  and  fat  metabolism  and  fat  metabolism  in  the  skeletal
muscles 40. Thus the high levels of natriureic peptides in heart failure may
explain  the  cardiac  cachexia  and  the  levels  of  natriuretic  peptides  in
obesity may explain the high fat mass.
Thus  there  is  a  homeostatic  mechanism  for  maintain  the  body
weight within a set-point. However, in obesity there is perturbation of this
inter-organ  crosstalk  in  the  form  of  hypothalamic  and  adipose  tissue
dysfunction;  defective  adaptive  thermogenesis  and  increased  gut
microbiota.
Nonexercise activity thermogenesis (NEAT)
The  new  concept  of  thermogenesis  is  nonexercise  activity
thermogenesis (NEAT). It is linked to obese population. It accompanies
physical  activities  like  daily  living,  fidgeting,  spontaneous  muscle
contraction,  and  posture  maintaining.  NEAT  contributes  2-3  of  daily
energy  expenditure  by  overfeeding.  The  fat  storage  seen  in  positive
energy individual is predicted by NEA. This mechanism is unknown 1.
ETIOLOGY OF OBESITY
Obesity is seen in families, and the heritability of body weight is
like  height.  Inheritance  is  not  Mendelian.  Not  only  genetic  factors
influence  the  obesity.  The  environment  shared  by  the  same  family
members  eating  habits  and  sedentary  life  also  takes  parts  in  obesity.
Adoptees resemble their biologic than adoptive parents, indicates genetic
influences. There is one theory called hypothesis of thirfty genotype. In
this  genes  that  are  useful  in  our  ancestors  survival  are  attenuated  by
environments in where food is available plenty in all time. 
Specific genetic syndromes
Obesity  caused  by  number  of  mutations  in  genome.  ob gene
mutation  represented  a  major  role.  The  ob/ob  mouse  develops
overweight, ER, and hyperphagia.  ob gene is the peptide leptin, a name
derived from the Greek root leptos, meaning thin. The ob gene is present
in  humans.  The  most  prominent  of  these  is  hypogonadotropic
hypogonadism,  which  is  reversed  by  leptin  replacement  in  the  leptin-
deficient subset. 
There is no evidence that mutations in the leptin or leptin receptor
genes  play  a  role  in  obesity.  The  absence  of  Proopio-melnanocortin
causes  secondary adrenal  insufficiency due to absence of  ACTH, pale
skin and red hair due to absence of alpha-MSH. Α-MSH binds to the type
4  melanocortin  receptor  (MC4R),  a  key  hypothalamic  receptor  that
inhibits eating. 
Syndromes of obesity  
 At  least  12  genetic  loci  have  been  identified,  and  most  of  the
encoded proteins from two multiprotein complexes that are involved in
ciliary function and microtubule-based intracellular transport. Mutations
might  disrupt  leptin  receptor  trafficking in  key  hypothalamic  neurons,
causing leptin resistance. Syndromes of obesity is shown in Table 3 1. 
Fig. 8. Mechanism of adipose tissue and inflammation
Truncal and Abdominal Adiposity
Truncal obesity is an important cardiovascular risk factor. This can
be due to excess abdominal adipose tissue, both intra-abdominal adipose
tissues  (IAAT)  and  subcutaneous  adipose  tissue  (SCAT).  Visceral
adiposity  is  a  metabolically  active  organ,  strongly  related  to  IR.
Adipocytes  of visceral  fat  have a different  histology and biology than
subcutaneous tissue fat. It is contains large insulin resistant adipocytes,
has  a  developed  vasculaturity  with  the  infiltration  of  inflammatory
macrocytes.
Asians  have more  truncal  SCAT.  It  was  measured by  skin  fold
thickness. high insulin resistance in a BMI and body fat matched Indian
men could be explained by more truncal skinfolds. 
Fatty liver is considered to be ‘innocuous’. In absence of alcohol
intake of   greater than 20 gram/day, it is called as non-alcoholic fatty
liver disease (NAFLD). 
Intra-myocellulor lipids (IMCL) are important in insulin resistance
and  measured  non-invasively  using  proton  magnetic  resonance
spectroscopy. Intra-myocellulor lipids is located in the mitochondria. The
soleus  muscle  IMCL  content  is  an  important  marker  of  Whole-body
insulin  sensitivity.  Increase  Intra-myocellulor  lipids  content  is  seen  in
soleus muscle in Indians with viceral obesity. 
Soleus  muscle  Intra-myocellulor  lipids  content  and  C-reactive
protein  levels  were  higher  in  T2DM  patients.  Soleus  muscle  Intra-
myocellulor lipids composition not correlated with IR and CRP levels.
Acanthosis nigricans is  a important marker for DM type 2 in Indians.
Truncal is seen in cushing diseases and lipodystrophy of HIV patients
treated by ART. It is highly related with IR and metabolic syndrome.
Adipocyte Size
Visceral adipose tissue has 4 times the number of glucocorticoid
receptors  as  SEAT adipose tissue with  similar  Kd values.  Lipoprotein
lipase activity  in  SCAT was  2  to  4  folds  lower  compared to  visceral
adipose  tissue.  Correlation  between  Lipoprotein  lipase  activity  and
glucocorticoid binding was seen. 
In subcutaneous adipose tissue, whereas LPL activity was higher in
omental  than in subcutaneous adipose tissue in both male and female.
These results show that there are differences between deposits of fat in
their  response to  glucocorticoids  and display  wide differences  in  their
biochemical properties. 
The gluteal region fat cells from women has high insulin receptor
binding and high rates of non-insulin-stimulated and maximally insulin-
stimulated rates  OF GLUCOSE transport  and glucose metabolism and
leptin  mRNA  is  markedly  expressed  in  abdominal  subcutaneous
adipocytes  than  with  visceral  adipocytes.  There  is  inverse  correlation
between adipocytes, PPAR-gamma and Bodymassindex. 
SCAT produces  low interleukin-6  (IL-6)  and  coriticoterone  and
high TNF-alpha in comparison to mesenteric adipose tissue. Since PPAR-
gamma is involved in adipocytes  development and insulin sensitivity and
has a negative control on TNF-alpha synthesis indicating the indicate that
complex  local  network  of  process  in  the  regulation  of  adipocytes
accumulation,  metabolism  and  function.  The  functional  differences  in
between  various  depots  of  adipose  tissue  indicate  that  they
have role in MS. 
Insulin resistance is the state where a given concentration of insulin
gives  below  normal  response  on  target  organs  like  skeletal  muscle,
adipose tissue and liver. Stimulation of the rennin system in the vessels
and cardio vascular system produces elevated level of Angiotensin II. It
has atherogenic effects.
Elevated  abdominal  fat  is  a  important  marker  of  arterial
hypertension.  There  is  a  correlation  between  weight  and  Bp,  with  70
percent of hypertension in male and 60 percent in female being directly
attribute to excess fat. Visceral fat is thought to be a metabolically active
tissue, highly related to insulin sensitivity. 
Adipose tissue is known to secrete a large number of adipokines
such as leptin, adiponection, PAI-1, TNF-alpha, IL-6, angiotensin II, FFA
and  resistin.  These  factors  contribute  the  process  of  inflammation
endothelial  malfunction,  atherogenic  and  hypertension.  Sympathetic
system activity also contributes to the effect of hypertension.
In  abdominal  obesity  there  is  deficiency of  adiponection,  “good
guy adipokine”. Adiponection reduces the insulin resistance. This exerts
antibiotic, anti-inflammatory and antiatherogenic effects. Thus there is an
inverse  relationship  of  adiponection  and  mean  arterial  pressure  so,
adiponection was a marker of hypertension.
INFLAMMATORY  BIOMARKERS,  ADIPOSE  TISSUE,  AND
OBESITY
leptin and adiponectin as well as a number of other cytokines that
are involved in inflammation 41.
With the onset of obesity, secretions of adipokines from adipose
tissue  change.  The  number  and  localization  of  immune,  vascular,  and
structural cells within adipose tissue change with weight gain and loss. In
addition, the location of the fat depot alters expression and secretion of
adipokines  with  visceral  fat  generally  having  a  higher  secretion  of
adipokines.
 Adipose tissue can also be present in organs including the heart,
liver, and kidney, as well as in bone marrow and lungs. The ramifications
of fat depots in these organs are not entirely known, but they appear to
increase an individual’s health risk for morbidity and mortality.
 Obesity results in   rise of these pro-inflammatory adipokines as
well as fall in the anti-inflammatory adipokine 42, 43. It is the raised levels
of circulating hormones and adipocytokines in the body that  has lead,
obesity  being  as  a  state  of  chronic  low-grade  inflammation,  further
linking it to disease etiology 44, 45. 
The process of inflammation is complex as it involves many cell
types  and  molecules  performing  various  functions,  these  include
initiation,  amplification,  attenuation  and  resolution.  Inflammation  is
assessed by biomarkers, with some released in part by adipose tissue, or
by  other  tissues,  with  their  release  being  stimulated  by  signalling
molecules  from  adipose  tissue.  Many  inflammatory  molecules  have
multiple functions and contribute to both the increase and decrease of
inflammation at various time points 46. 
Commonly assessed biomarkers  for  inflammation include leptin,
TNF-alpha, interleukin (IL)-6, adiponectin and serum C-reactive protein
(CRP).  Leptin,  TNFα,  IL-6  and  CRP are  known as  pro-inflammatory
cytokines as they induce inflammation whereas adiponectin is known as
an  anti-inflammatory  cytokine  as  it  acts  to  help  reduce  inflammatory
pathways 47.
C-REACTIVE PROTEIN (CRP)
CRP PHYSIOLOGY
C-reactive  protein  (CRP)  is  a  calcium-dependent  ligand-binding
plasma  protein  in  the  pentraxin  family.  The  human  CRP  molecule  is
synthesized  by  hepatocytes  and  is  composed  of  5  identical
nonglycosylated polypeptide subunits, with 206 amino acid each 48. 
Serum CRP binds with highest affinity to phosphocholine residues,
though it binds with a number of other autologous and extrinsic ligands;
it aggregates or precipitates the cellular, particular, or molecular structure
of these ligands. Serum C-reactive protein was first detected by Tillet and
Francis in 1930 with their identification of a substance in the serum of
acutely infected by pneumococcal pneumonia inspection. 
It forms PPT with polysaccharide capsule of St. Pneumonia. This
indicates  body  chemical  reaction  to  inflammation.  It  is  not  unique  to
pneumonia,  also  seen  in  other  acute  conditions  49.  From  those  days
onwards  serum CRP  has  been  used  as  a  screening  device  for  occult
inflammation, as a marker of disease activity, and as a diagnostic tool.
While systemic inflammation and the inflammatory cascade may
have  sources  other  than  atherogenesis,  increased  recognition  of  the
inflammatory  component  of  the  atherosclerotic  process.  It  used  as  a
marker of endothelial injury and atherogenesis.
In  healthy individuals,  levels  of  CRP are  normally  less  than 10
milligram/dl: the median concentration of CRP is 0.8 milligram/litre; the
90th centile is 3.0 milligram/litre; and the 99th centile is 10 milligram/litre
(Shine, 1981). In acute phase stimulus, however, CRP values can increase
from less than 50 microgram/dl to over 500 milligram/litre, a 10,000-fold
increase. 
Serum CRP level is not altered in other conditions of health and
disease,  circulating CRP level  is  directly the rate of  synthesis  50.  This
synthesis  rate  is  a  direct  reflection  of  the  pathological  processes
stimulating CRP production. The stimuli for synthesis disappear, serum
CRP  level  drops  at  the  rate  of  CRP  clearance.  CRP  values  tend  to
increase with age and this change is presumed to reflect an increase in
subclinical pathologies (Hutchinson, 2000). 
The people have constant CRP level for each person. Serum CRP
indicates  inflammatory  process  and  tissue  injury.  In  acute-state  serum
CRP values indicate no seasonal or diurnal variation and are not affected
by  eating  habits.  Liver  failure  is  the  only  concurrent  pathology  that
impairs serum CRP production, and few drugs reduce serum CRP levels
unless they act upon the underlying pathology that provides the acute-
phase  stimulus  for  CRP  production.  Levels  of  serum  CRP  closely
associated  with  inflammatory  markers.  It  also  predicts  severity  of
coronary  insult  51.  So  the  CRP  levels  are  highly  associated  with
cardiovascular diseases and its prognosis.
The American Heart Association and Centres for Disease Control
released  a  Scientific  Statement  in  2003  indicating  that  inflammatory
markers used to classify risk assessment to identify persons. From this
basis they are advised for lipid-lowering,  anti-platelet,  or  cardiac drug
therapies.  Also  included  were  those  for  whom  there  should  be  an
increased emphasis on therapeutic lifestyle changes.
 Cesari,  et  al  studies  shows  serum  levels  of  the  inflammatory
markers CRP, IL-6, and TNF-α are well correlated with strok, CAD, SHT
and  CHF.  These  3  inflammatory  markers  indicate  prognosis  of  the
disease. Among this IL-6 being the strongest predictor for CHF and IHD.
Because of the economic ease of testing for CRP, however, it maintains
its  importance the  most  suitable  inflammatory  marker  for  wide-spread
testing. 
Providing  considerable  evidence  that  CRP  can  offer  striking
predictive  significance  for  cardiovascular  disease52.  The  AHA/CDC
shows that their dose response relationship between the level of serum
CRP  and  incident  of  IHD.  CRP  is  currently  the  best  candidate  for
measures of inflammation. 
Individuals with CRP levels of <1 are categorized as being at a low
risk of cardiovascular disease, those with levels 1.0 to 3.0 are categorized
as being at an average risk of cardiovascular disease, and individuals with
CRP levels  greater  than  3  are  categorized  as  being  at  a  high  risk  of
cardiovascular disease 53.
Fig. 9. Consequences of obesity
Cardiovascular System Respiratory  SYSTEM
Systemic hypertension          Breathlessness
CHF ,  CAD OSP
Right heart failure Hypoventilation syndrome
Varicose veins of  legs Pickwickian syndrome
Embolism of  Pulmonary  vessels Bronchial   Asthma
Endocrine system Gastrointestinal SYSTEM
Metabolic syndrome [ms] GERD
Type 2  DM         NAFLD
LIPID Abnormalities         Gall stones
PCOD         Carcinoma of  colon
Musculoskeletal SYSTEM Genitourinary system
High uricacid level Stress incontinence  of urine
      Physical inactivity Obesity-reated glomerulopathy
OA (knees and hips)         Male  Hypogonadism 
LBA Cancer of Breastand    uterus
      Entrapment neuropathy         PIH
Psychological   disorder Central  nervous system
Depression          Cerebrovascular accident
Body image disturbance          Intracranial hypertension
Social stigma Meralgia paresthetica
Table 4. Obesity-related Organ Systems Review
PATHOLOGIC CONSEQUENCES OF OBESITY
There is strong association between obesity and CAD, DM type 2,
and  chronic  illness;  there  is  substantial  increase  in  obesity  associated
diseases in future. 
CARDIOVASCULAR DISORDER, SYSTEMIC, HYPERTENSION
AND CCF
 This  occur    due to rise in blood volume, which increase  left
ventricular filling, a rise   in stroke volume and an increase in cardiac out
increase in  cardiac output is  caused  by structural change, and is not
affected  by heart rate (HR) and  HR remains unchanged. The obesity
affects IHD by arrhythmias, PVD and CVA, SCD. Atherogenesis forms
by a progression of plaque formation and rupture. It leads to thrombus
formation and fibrosis. 
Fig. 10 Related hormones in Obese
Arrhythmias
Ventricular ectopics present 10 times greater in obese persons than
normal weight persons. The common arrhythmias are sinus arrhythmia,
PVC, APC, VT, and SVT. 
CVA and Peripheral Vascular Disease (PVD)
In obesity there is increased risk of ischemia and atherosclerosis
obesity is associated with increased intimal thickening of carotid arteries,
and thus, overweight alone can increase the risk for stroke 54.
Sudden Death (SCD)
The study of Framingham Heart states that the sudden death is a
predictive for overweight and obese male and female.
Gallbladder Disorders
In obese populations gallstones are having a high prevalence rate.
The formation  of  gallstone  needs  2  conditions:  (1) secretion  of
supersaturated bile and stasis in gallbladder. Obesity affects bile content
and motility  of  gallbladder.  (2)  Bile  is  more saturated  with  high
cholesterol.  This  can  cause  gallbladder  motor dysfunction  1.  Recent
studies show that leptin may cause the association between obesity and
gallstones. The gallstones incidence in obese women is estimated at 2.6
per 100 person-years 55.
Sleep Disorders
There is strong associations are between obesity and OSA. Weight
gain and loss can affect the severity of OSA depends on body weight.
Approx 10-15 percent of severe obese persons develop OSA.  In this CO2
retention occur during wakefulness. This is called obesity-hypoventilation
syndrome.  The  probable  mechanism  includes  genetics  in  ventilatory
responses  and  the  metabolic  effects  of  obesity,  respiratory  control.
Cardiovascular  or  metabolic  effects  also  involved  in  obesity  on
respiratory control 56.
Obesity and liver disease (NAFLD) Non-alcoholic fatty liver disease
FFA is thus increased in obesity due to increased release from the
adipocytes and decreased oxidation. FFA impairs insulin signalling by
two  mechanisms.  One  is  via  the  increased  accumulation  of  the  lipid
intermediaries like diacylglycerol and ceramides. The other mechanism is
by stimulating the NFκβ pathway via the TLR4. 
However FFA cannot bind TLR4 directly, and recently it has been
shown that the hepatokine fetuin A is an endogenous ligand for TLR4 and
presents FFA to TLR4. 
Fetuin  A also  decreases  the  release  of  adiponection  in  obesity.
Cytokines  released  from the  inflamed  adipocytes  stimulates  the  NFκβ
which impairs insulin signalling. Thus the above mentioned factors result
to insulin resistance in obese people.
The  gut  micrboime  inhibits  the  FIAF,  a  natural  inhibitor  of
lipoprotein lipase. In absence of FIAF, the lipoprotein lipase activity is
increased in obesity resulting in increased fatty acid. Increased fatty acid
thus absorbed is delivered to the liver via portal veins and to the adipose
tissue via chylomicrons. 
Recently  it  was  shown  that  IL-1β  released  during  adipose
expandability and thus favours ectopic fat deposition in the liver. 
The fatty liver releases an inflammatory cytokine fetuin-A which
has a pathogenic role in insulin resistance. Feutin A decreases the release
of anti-inflammatory adipokine adiponection from the adipocyte. Adipose
tissue  dysfunction  causes  NAFLD  and  NAFLD  further  worsens  the
adipose tissue dysfunction.
Insulin resistance and NAFLD are associated with macrovascular
complications like atherosclerotic cardiovascular  disease.  NAFLD may
be related with the lipid abnormalities of MS characterized by a small
dense LDL-C, with elevated triglycerides (TGL) and decreased in HDL.
ENDOTHELIAL DYSFUNCTION 
Vascular  endothelial  dysfunction  is  a  main  cardiovascular  risk
predictor and is usually starter for the process of arterial atherosclerosis.
The endothelium is one of the largest organs of the body and actively
produces  a  huge  variety  of  molecules  which  can  act  as  agonists  and
antagonists nullifying their effects.
Fig. 12. Adipokines on endothelium    
Eendothelial  cell  act  as  a  receptor  –  It  contains  effect  or  structure
which senses various physical or chemical stimus that present innerside
of the vessel.  
Table 5. Equilibrium of endothelial function
1. Endothelium –derived relaxing factors(EDRF) (Vasodilators)
Substances:
• NO - Nitric Oxide 
• Endothelium –derived hyperpolarizing factor
• Bradykinin
• Adrenomadullin
• Atrial natriuretic peptide
Their overall effects:
• Vasodilatation
• Anti-thrombotic
• Anti-inflammatory
• Anti-oxidative stress
2. Endothelium – derived vasoconstrictors
Substances:
• Endothelin-1
• Angiotensin II
• Thromboxane A2
• Oxidant radicals
• Prostaglandin H2
Their overall effects: 
• Vasoconstriction
• Increased thrombosis
• Increased inflammation
• Increased oxidative stress
“Endothelial  dysfunction” (En D) means there  is  loss  in normal
physiology  of  endothelium.   Normal  properties  of  endothelium  were
dilation of the vessels increased in fibrinolysis and prevention of platelet
aggregation.
 Vascular  endothelial  cells  are  unable  to  find  their  ability  to
maintain  the  balance  between  the  opposite  forces  and  this  result  in
dysregulated  endothelium  and  disturbed  cardiovascular  homeostasis.
Lipids  and leucocytes  (Monocytes  & T-Lymphocytes)  invade  such  an
endothelium inciting an inflammatory response and appearance of fatty
streaks.  
Inflammation and Endothermal Dysfunction
Chronic low grade inflammation is associated with IR & En D. C-
reactive  Protein  (CRP),  IL-6,  TNF-α  and  increased  PAI-1  have  been
shown to be elevated in IR state. Microalbuminuria has also considered as
urinary marker indicative of ch0ronic inflammation and is increased in
MetS. 
All  of  these  are  surrogate  markers  of  En  D.  in  patients  with
abdominal  obesity,  increased  adipocyte  expression  of  fatty  acids  and
cytokines  that  include  IR  may  be  the  underlying  mechanism  linking
inflammation  and  MetS.  Factors  such  as  over  nutrition,  physical
inactivity and ageing cause cytokine hypersecretion and eventually lead
to  IR  & DM in  persons  with  genetic  or  /  and  metabolic  profile  that
predispose to these conditions. 
Perivascular adipose tissue, endothelium and MetS
Perivaascular  PAT (adipose tissue) means,  Fatty  tissue around
the  arteries  large  (aorta,  coronaries)  or  small  (vascular  beds  of  the
mesentry,  smooth muscle,  renal  and fatty tissue depots).  Perivaascular
adipose tissue consists of fibroblasts, adipocytes, mast and stem cells, and
neurons. 
Most  of  the  study  shows  that  the  Perivaascular  adipose  tissue
(PAT) secretes a variety of adipokines like adiponectin and leptin among
others  which  contribute  regulation  of  vascular  function.  With  CAD
production  of  adiponectinis  reduced  in  epicardial  adipose  tissue.
Adipokines such as FFA, TNF-alpha and adiponectin  are important  in
insulin resistance and inflammation.
Fig. 13. Adipocytes and its substance action
Vascular  endothelium  is  a  main  modifier  of  vascular  tones.
Perivaascular  adipose  tissue  modifies  the  association  between
endothelium-dependent  vasodilator  (EDRF-NO)  and  vasoconstrictor
substances such as endothelin-1.
Perivaascular adipose tissue around the micro vascular bed, derived
from the subcutaneous fat around the gluteal region .Healthy lean people
also  has  anticontractile  properties  of  this  bed.  Leptin  hormone  and
adiponection factor play a role in perivaascular adipose tissue associated
endothelium-dependent vasodilation.
Inflammation: the link between obesity and diabetes
The  family  of  NLR  (Nod-like  receptor),  innate  immunity  cell
sensors, like the leucine-rich-containg family, nucleotide-binding domain,
pyrin domain-containing-3(Nlrp3), but alsoknownas Nalp3or cryopyrin)
inflammasome  are  implicated  inrecognizing  certain  non  micro  bial
originate of ‘danger signals’. It leads to activation of caspase-1 and that
activates interlukin-1beta (1l-1beta) and IL-18 synthesis.
Sl.
No
.
Risk IDF (2005) NCEP ATP IIICriteria WHO (1999)
I
Obese/ 
Visceral 
obesity
Waist 
circumference ≥ 
90 centi metre in
male,
≥ 80 centi metre 
in female,– In 
South Asians
Waist circumference
≥ 102 cm (M),
≥ 88 cm (F)
Body mass index ≥ 30 
kilogram/m2 and/or waist-
to-hip ratio > 0.90 (Male),
> 0.85 (Female)
II
Blood 
pressure(B
P)
≥ 140/ ≥ 90 mm Hg 
III.
Fasting 
glucose(FB
S)
≥ 100 mg/dl 
or/and  pre-
existing DM
≥ 110 mille gram/dl Diabetes, IGT or IR
IV
Triglycerid
es
≥ 150 mille gram
/dl
≥ 150 mille gram /dl ≥ 150 mille gram /dl
High 
density 
Cholesterol
< 40 mille 
gram /dl (Male),
< 50mg/dl 
(Female)
< 40 mille gram /dl 
(M),
< 50mg/dl (F)
Metabolic 
syndrome -
definition
Atleast 3  risk 
factors
DM, IGT or IR plus any 
two or more risk factors
Table 6. Obesity and metabolic syndrome criteria
Fig. 14. Obesity and metabolic syndrome
Fig. 15. Visceral fat and insulin resistance
INSULIN RESISTANCE 
Insulin action:  It is the effective anabolic hormone having a main
role  in  carbohydrate,  fatty  acid  and  protein  metabolism,  growth  and
differentiation of cells, and vascular endothelial function. 
Fig. 16. Insulin signalling and the regulation of glucose and lipid
metabolism
The glucoregulatory  effects  are  by  predominant  action  on  three
tissues: liver, muscle and adipose tissue.
The receptor of insulin can autophosphorylate and phosphorylate
the substrates that is important for difficult cellular responses to insulin.
Transphosphrylation of insulin receptor substrate (IRS) leads to activation
of  proteins  1-4.  It  leads  to  the  activation  of  downstream  signaling
pathways. It can mediate insulin actions. IRS-1 has prominent action    in
the skeletal  muscle and IRS-2   action in the liver.  Path ways of two
major  signals  activated  by  insulin  binding  to  its  receptor  are  the
phosphatidylinositol-3-kinase  (PI3K)  pathway  and  mitogenic,  or
mitogen-activated protein kinase (MARK) pathway. Insulin resistance is
states that the below normal biologic response to a given concentration of
insulin. 
Primary vs secondary insulin resistance
Intrinsic  (primary)  defects  in  insulin  sensitivity  caused  by
mutations  of  any  protein  and  the  final  insulin-regulated  proteins.
Impairments in cellular events between insulin and its surface receptors
leads to insulin resistance (IR) . It is called type A or secondary insulin
resistance.
In secondary insulin resistance insulin sensitivity returns to normal
after  the  removal  of  the  factor  or  state.  Cortisol,  glucagon,
catecholamines, and GH can promote insulin resistance (IR).  In infection
and  stress  conditions  these  hormones  are  secreted  in  excess  leads  to
down-regulates  insulin  receptors.  Increased  levels  of  insulin  down-
regulates its receptors.
Another factor that affects sensitivity of insulin is auto antibodies
to the insulin receptor.  These antibodies are typically  IgC and usually
associated with other characteristics of autoimmunity.
Type A and type B resistance
In type A insulin resistance is inherited prototype.  It is a syndrome
of severe IR. It is categorized increased level of insulin .There may be
associated  with  IGT,  acanthosis  nigicans  and  hyperandrogenism.
Leprechaunism  and  lipodystrophy  are  classical  examples.  Type  B
resistance  is  due  to  antibodies  to  insulin  receptor  which  may  be
associated with other autoimmune disease.
Obesity is associated with kidney disease via direct  and indirect
mechanisms. Indirect mechanisms include the association of obesity with
hypertension, diabetes mellitus and atherosclerotic cardiovascular disease
which are at risk factors for chronic kidney disease.
OBESITY AND HYPERTENSION
Fig. 17. Obesity and Hypertension
Obesity, kidney and liver
Fig. 18. Development of NAFLD and Obesity
Severely obese persons develop albuminuria with hypertrophy of
podocyte,  mesangial  proliferation  and  glomerular  hypertrophy
enlargement, and focal segmental glomerular sclerosis in the absence of
DM and SHT.
Fetuin-A  and  adiponection  may  have  a  role  in  linking  obesity,
chronic kidney disease and NAFLD. Feutin-A levels are high in obese,
NAFLD and obese with CKD. Adiponection levels have been found to
inversely  correlative  with  proteinuria.  Fetuin-A,  a  hepatokine  released
from the  liver  inhibits  adiponection secretion from the  adipose tissue.
AMPK acts as a gauge for cellular energy reserve and is stimulated in
states of energy depletion. AMPK also inhibits the generation of reactive
oxygen species by suppressing an isoform of NADPH oxidase. 
Normally  adiponectin  stimulates  the  AMPK activity  resulting in
stimulation of ATP producing catabolic pathway and inhibition of ATP
consuming anabolic in obesity, a state of energy excess associated with
low adiponection levels. When AMPK is chronically deactivated due to
calorie  excess  there  is  both  lipogenesis  and  increased  cellular  protein
synthesis. 
This along with oxidative stress results  in podocyte hypertrophy
with effacement of its foot process of the glomerulus, steatohepatitis and
ultimately  fibrosis  due  to  reactive  oxygen  species  and  endoplasmic
reticulum stress.
Osteo-sarcopenic obesity
Obesity  believed  to  improve  bone  mass  due  to  the  mechanical
effects of loading, increase in bone anabolic factors like hyperinsulinemia
and increased estrogen due to increased aromatase activity. Bone mass
has been found to be decreased in obesity.
 Sarcopenia (loss of lean mass) is frequently seen with aging and is
frequently associated with osteopenia. Obesity which may be considered
a form of accelerated aging is frequently associated with loss of muscle
mass  and  bone  mass.  The  condition  has  been  aptly  termed  ‘Osteo-
sarcopenic obesity’.
Inverse  bone  fat  relationship.  Both  arise  from  the  same
mesenchymal stem cells, so when adipogenesis occurs, oteoblastogenesis
is inhibited. Chronic inflammatory state of obesity results in the release
of inflammatory cytokines that promote osteoclastic bone resorption by
stimulating RANK/RANKL pathway. Obesity is associated with vitamin
D deficiency which further impairs bone health.
The  muscle-bone  relationship  is  direct.  Improved  muscle  mass
improves  bone  health  by  the  dynamic  and  static  effect  of  loading.
Contracting  muscles  are  known  to  secrete  ‘myokines’  which  have
beneficial  effects  on the bone,  adipose tissue and improved metabolic
effects as opposed to adipokines. The important myokines include IL-6,
myostatin, follistation, irisin etc.
Interleukin 6 (IL-6)
It is the first myokine described and is released in the circulation
from the exercising muscles. It acts as an energy sensor and is released
following muscle glycogen depletion. Sudden increasing levels of IL-6
increases fatty acid oxidation, glucose uptake and osteo protective and
anti-inflammatory action. 
This has somewhat paradoxical because IL-6 levels are known to
be  increased  in  type  2  diabetes  and  cardiovascular  disease.  Recent
evidence  points  to  the  fact  that  IL-6  could  be  a  marker  of  insulin
resistance rather than a cause of it and obesity could be a state of IL-6
resistance resulting in increased levels.
Folistation
Following  exercise  a  beneficial  myokine  follistatin  is  released
which  is  a  physiological  antagonist  of  myostatin.  Myostatin  increases
with  physical  inactivity,  inhibits  growth  of  muscles  and  promotes
increase  in  adiposity.  Thus  exercise  decreases  the  myostatin  levels
resulting in increase in muscle mass and decrease in fat mass.
Irisin
Another  myokine  released  from the  exercising  muscle  is  irisin.
Irisin has been responsible for the ’browing’ of the white adipose tissue
resulting  in’  beige’  or  ‘brite’  adipocytes.  These  brite  adipocytes  are
believed to have the same thermogenic potential as brown adipocytes and
thereby result in decrease result in decrease in fat mass and weight loss.
Improvement  in  the  bone mass  results  in  release  of  factors  like
osteocalcin,  osteoprotegerin  and  diminished  osteopontin.  These  bone
factors especiaaly osteocalcin has been found to improve insulin secretion
and sensitivity. Osteopontin on the other hand has been linked to obesity
and NAFLD.
Obesity and PCOS
Obesity and PCOS are closely related. In USA the prevalence of
obesity in women with PCOS is 80%. Many women with PCOS have
central obesity and upper abdominal obesity is associated with increased
androgen production.
 In PCOS an increase in the subcutaneous adipocyte size (which
are more insulin resistant), decreased lipolytic effect of catecholamines
on  subcutaneous  adipocytes  and  increased  lipolytic  activity  on  the
visceral adipocytes. Increased delivery of FFA in the portal circulation
leading to hepatic insulin resistance. It acts on  reproductive system and
body  metabolism.  It  action  as  a  co-gonadotropin  through  its  cognate
receptor to modify steroidogenesis of ovary. Supra physiological doses of
insulin, as seen in PCOS augment androgen production.
 Insulin  signals  in  the  central  nerves  system  in  important  for
ovulation. This signaling is impaired in obesity and PCOS due to CNS
insulin  resistance.  Hyperandrogenemia  in  PCOS  can  produce  insulin
resistance by directly affecting the insulin action on voluntary muscles
and fatty tissue, by altering the adipokine secretions, and by raising the
abdominal adiposity.
Obesity and cancer
Obesity  is  associated  with  colon  cancer,  CA  breast,  CA
endometrial,  renal  malignancies,  and  adenocarcinoma  of  esophageal.
Obesity  has  also  been  implicated  in  the  occurrence  of  hematological
malignancies  like  non-Hodgkin’s  lymphoma,  leukemia,  and  multiple
myeloma;  thyroid  cancer;  pancreatic  cancer;  gallbladder  cancer;  high-
grade prostate cancer; and ovarian cancer. 
Insulin may promote mutagenesis by acting via the insulin or IGF-
1 receptors. Low adiponection levels in obesity may be linked to cancer
development  and  progression.  Adiponection,  the  important  protein
secreted by adipose tissue, exhibits insulin-sensitizing, anti-inflammatory,
anti-atherogenic, pro-apoptotic, and anti-proliferative properties.
Obesity in south Asians
1. Urbanization
2. Less physical activity
3. High carbohydrate, high fat and low fiber food
4. Lower intake of w-3 PUFAs
5. Increased life expectancy of the elderly population
6. Migration from villages to cities
7. Stress and Alcohol and tobacco consumption
Metabolically obese Asian Indians
Asian and Indians could be classified as ‘metabolically obese’, i.e.
they have several metabolic derangements but are ‘non-obese, by usual
BMI standards. These non-obese persons usually have elevated body fat,
visceral adiposity, thick truncal SCAT and ectopic fat deposition features
often  seen  South  Asians.  This  pheno  type  contributes  to  IR,
hyperglycemias, dyslipidemia, and excess pro-coagulant factors 57. 
Relevance of Abdominal obesity and Asian Indian visceral fat
Distribution  of  fatty  tissue  is  an  important  marker  of  obesity
associated morbidity and mortality in humans. It can be associated with
genetic cause, hormonal and environmental factors. Womens have more
subcutaneous  and  gluteal-femoral  region  adipose  tissue,  which  are
essentially absent in men. 
Men  have  a  greater  proportion  of  fatty  tissue  localized  intra-
abdominally. The gluteal-femoral adipose tissue is specifically enlarged
in  women.  This  has  more  lipoprotein  lipase  (LPL)  activities.  Women
have the unique ability to protect visceral deposits from adipose tissue
accumulation.
 It is not seen in male. Whereas in males deposition of excess fat in
this region parallel with other depots. This difference in the distribution
of fat is attributed to the action of female sex steroid hormones on the
regulation of adipocytes metabolism in concert with cortisol, which has a
regularity role on LPL. 
MNOW-Definition
Obesity is heterogeneous disorder with several possible etiologies,
and  obese  persons  do  not  show  a  clustering  of  metabolic  and
cardiovascular risk factors. Similarly, all lean persons do not present with
a healthy metabolic and disease-free profile. “Metabolic Obesity”, means
the reference to visceral fat deposition in either lean or obese individuals. 
It can identify the high for cardiovascular disorder better than the
usually used definitions of obesity. Metabolically healthy obesity (MHO)
indicates  the absence of any overt cardiometabolic disorder, in particular,
type 2 diabetes, dyslipidaemia and hypertension in an individual with a
BMI>30 kg/m2. 
In contrast, MONW individuals are characterized by presence of
these diseases, even though they are not obese. In the nonexistence of
pathologies, the correlation and clustering of cardio metabolic risk factors
or inflammatory markers have also been used to categorize subjects as
metabolically normal or abnormal 58.
Fig. 19. Obesity spectrum (Four subtypes of obesity) 
MONW-Metabolically Obese Normal Weight
In the recent past research has particular point on group of obese
persons  who  are  “metabolically  healthy”  (MHO)  or  “metabolically
normal” (MNOB) despite raised adiposity. Some studies have shown that
these individuals may not be at elevated risk for mortality, and treatment
for obesity may be unnecessary.
Four  categories  of  individuals  may  be  identified  in  population
based on BMI values (<30 or >30 kg/m2) and presence or absence of
metabolic  derangements-Metabolically  Abnormal  Obese  [MAO,  also
termed  Metabolically  Resistant  Obese  (MRO) or  Metabolically  Obese
Obese (MOO)],  Metabolically  Normal  Obese  [MNOB, also  termed as
Metabolically  Healthy  Obese  (MHO)],  Metabolically  Obese  Normal
Weight  [MONW,  also  termed  as  Metabolically  Obese  Non  Obese
(MONO)],  and  Metabolically  Healthy  Normal  Weight  [MHNW,  also
termed as Metabolically Healthy Non Obese (MHNO)].
Obesity in Asian Indians
Asians generally have a lower body-mass index as compared to
their western counterparts, and they differ from European populations in
relations between body-mass index and percentage of body fat and health
risks.  Indians  have  high  percentage  of  body  fat,  abdominal  obesity,
hyperinsulinemia and low muscle mass. In particular, visceral obesity is
common in South Asians,  and evident even in non-obese people. That
possibly explains why Asian Indians have a elevated risk of developing
obesity related diseases and mortality at lesser levels of BMI.
Asian Indian Phenotype
Elevated predisposition to diabetes and premature coronary artery
disease  in  Indian  may  be  attributable  to  the  so  called  ‘Asian  Indian
Phenotype’.  Indian  phenotype  is  characterized  a  larger  central  body
obesity as shown by larger waist circumference (WC) and waist-to-hip
ratios  (WHR) associated  with  a  relatively  smaller  BMI,  a  measure  of
generalized obesity.
 This cause to unique biochemical and hormonal changes including
more  plasma  insulin  levels,  greater  insulin  resistance,  lower  HDL-
cholesterol,  higher  triglyceride  levels,  increased  small  dense  LDL-
cholesterol, and decreased adiponection levels. Many Indians fit into the
category of metabolically obese, normal weight persons 59.
Understanding MONW
In  the  year  of  1980s,  more  investigators  began  to  identify  the
existence  of  different  subtypes  of  obesity.  In  1981,  Neil  Rudderman
reported  the  initial  description  of  Metabolically  Obese  but  Normal
Weight  (MNOW)  phenotype,  defined  a  subgroup  of  normal-weight
individuals displaying obesity-related characteristic. 
It was suggested that there are individuals who by standard weight
tables  are  not  obese  or  even  overweight,  but  who  have  metabolic
abnormalities  characteristically  associated with  adult-onset  obesity,  are
hyperinsulinemic,  insulin-resistant,  and  have  high  predisposition  for
developing type 2 diabetes, hypertriglyceidemia, and premature coronary
heart  disease.  It  was  also  suggested  that  these  MNOW  individuals
represent one end of spectrum of obesity and that some of them would be
difficult  to  detect  by any criteria.  And as  in theor  obese counterparts,
associated  metabolic  disorders  like  hypertriglyceridemia  and  type  2
diabetes in these individuals also would benefit from caloric restriction.
Metabolically  obese,  normal  weight  pheno  type  persons  are
common in our population .It can represent the one end of the spectrum
with insulin resistance syndrome (IRS).
MNOW in Indians
Limited data on prevalence of MNOW in India. A study assessing
association  of  obesity  and  coronary  risk  factors  in  a  North  Indian
community reported a high prevalence of diabetes (40/226, 17.7% in men
and 33/232, 14.2% in women), overweight and obesity (BMI>25) in both
men (123/226, 54.4%) and women (162/232, 69.8%). 
Interesting to note is that both men and women with BMI<25kg/m2
also had significant type 2 diabetes (16/103 men, 15.5%; 6/70 women,
8.6%), hypertension (men 35/103, 34%, women 19/70, 27.1%), high total
cholesterol  (29/103  men,  28.2%,  13/70  women,  18.6%),  high
triglycerides  (15/103,  14.5%  men,  18/70,  25.7%  women),  low  HDL
(79/103,  76.7% men,  29/70,  41.4% women)  and  metabolic  syndrome
(15/103, 14.6% men, 11/70, 15.7% women). This may be representative
of prevalence of MONW phenotype in this study population 60. 
Obesity paradox
When compared with normal subjects MONW individuals not only
have an abnormal and more atherogenic metabolic profile, they are also
predisposed to a higher risk of mortality as compared to their overweight
and obese counterparts-the Obesity Paradox 61.
“Obesity paradox” means that, although obesity is a important risk
factor  for  the  development  of  cardiovascular  and  peripheral  vascular
disease,  several  studies  has  shown  an  inverse  relationship  between
obesity and mortality.
When acute cardiovascular decompensation  occurs, like, primary
outcome in myocardial infarction, congestive heart failure, Post CABG,
during dialysis, during sepsis: obese patients may have a survival benefit.
This benefit also observed in normal healthy obese elderly men and
women, chronic hypertensives, diabetes and so on. 
Major hypotheses for this apparent survival effect include
1. Obese  patients  may  have  good  and  aggressive  medical  care  and
improved observation than normal-weight persons.
2. Obese  patients  are  more  and  better  medical  therapy  than  other
individuals.
3. Obese  patients  tend  to  be  young  at  the  time  of  diagnosis  of
cardiovascular disorder, which can give an age benefit to them.
4. Some experts claim the sample size of the existing studies on obesity
is still too small or too indecisive to make such determinations.
5. Other  investigators  suggest  the  way  we  measure  obesity  is
unsatisfactory and may explain some of the paradoxical results seen.
6. Patients  who  lose  weight  involuntarily  are  likely  to  have  severe
underlying  disease,  and  their  life  expectancy  might  be  shorter,  in
contrast  to  patients  who  lose  weight  intentionally  with  lifestyle
modifications, who have better outcomes.
These factors may lead to the false impression that obesity confers
some survival  advantage with  acute cardiovascular  stress  and in some
chronic  conditions.  Studies  shows  that  obesity  alone  may  confer  a
survival benefit independent of age, medical care, or therapy. 
Positive  inflammatory  status  correlated  with  metabolic  health  in
obese and nonobese individuals, and these observations may have health
and clinical significance in view of screening and stratification based on
metabolic health phenotype to identify those at greatest cardiometabolic
risk.  
MATERIALS AND
METHODS
MATERIALS AND METHODS
 Design          :   Prospective study.
Sample Size  :   100 Patients.
Duration of the study : August 2013 to July 2014
Inclusion Criteria
Adult  of  17  to  45years  with  BMI  of  More  than  25  kg/m2 are
selected.  The  persons  are  selected  from  OP  and  IP  department.  The
people attending master health check-up are taken for our study group.
WHO criteria for obesity is used for the sample grouping.
Table 1. Classification of obesity with BMI level
BMI (kg/m2) Obesity Class Risk of Disease
Under weight <18.5
Healthy weight 18.5-24.9
Overweight 25.0-29.9 Increased
Obesity 30.0-34.9 I High
Obesity 35.0-39.9 II Very high
Extreme obesity ≥40 III Extremely high
Exclusion criteria
Patient with following history were excluded from our study
Chronic Smoker
On chronic drugs, Self medication
Connective tissue disease like rheumatic arthritis, SLE
Systemic Hypertension 
Chronic illness like renal disorders and liver diseases
Cardiovascular diseases
Diabetes mellitus
Pregnancy, Menstrual abnormalities, patients with IUCD 
Mentally Retarded person
Hypothyroidism 
Written  informed  consent  was  taken  from  the  patient.  History
regarding patient life style, eating habits, household works done by them
is taken. Family history of obesity other chronic illness, occupation of the
patient, residency of the patient (rural or urban) was taken in detail. 
Detail  physical  examination  of  the  patient  was  done.  Patient
weight, height, waist circumference of the patient was measured. From
the weight and height, BMI was calculated.
Method of waist circumference measurement 
By using non stretchable flexible inch tape in horizontal position,
just above the iliac crest in normal end of the expiration while the patient
is standing. 
Blood sample was taken send for lipid profile,  blood sugar, and
serum C-reactive protein.
Serum C-reactive protein was measured by immunonephalometry
method. Two ml of blood was taken for serum C-reactive level. 
Patients  are  classified  into  three  groups  based  on  level  of  C-
reactive protein. Those with less than 1 mg per dl were taken as negative
group (low risk).
Patient with 1-2 mg per dl was grouped into moderate risk.
Those with  high C-reactive protein more than 3 mg per  dl  was
grouped in to high risk. These two groups taken as CRP positive group.
Risk level CRP (mg/L)
Low < 1.0
Average 1.0– 3.0
High >3.0
OBSERVATIONS
OBSERVATIONS
Average levels of SERUM CRP across Occupation
SERUM CRP (mg/L)
Occupation Mean Minimum Maximum No of Cases
Sedentary 2.46 0.00 5.20 61
Manual Labour 1.39 0.00 3.20 39
Total 2.05 0.00 5.20 100
Mean
2.46
1.39
SERUM CRP ( mg / l )
M EAN ACRO SS NATURE O F  O CCUPATI O N
Sedentary Manual Labour
ANOVA
SERUM
CRP(mg/L)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 27.29498164 1.00 27.29 9.36 0.00
Within Groups 285.7970694 98.00 2.92
Total 313.092051 99.00
Sedentary; 61
Manual Labour; 39
NO  o f  CASES Ac r o s s  NATURE O F  O CCUPATI O N
INTERPRETATION
 The  mean  of  SERUM  CRP  in  (mg/L) for  sedentary
occupation is 2.46 and 1.39 for manual labor.
 The Anova table indicates that the mean level between both
the categories is significantly different.
 The  conclusion  is  that  SERUM  CRP   is  highest  for
Sedentary  Occupation  as  compared  to  manual  labor
occupation.
Average levels of SERUM CRP across Urban and Rural Areas
SERUM CRP (mg/L)
Rural&Urban Mean Minimum Maximum No of Cases
Urban 2.62 0 5.10 50
Rural 1.47 0 5.20 50
Total 2.05 0 5.20 100
Mean
2.46
1.39
SER UM C R P ( mg / l )
M EAN ACR O SS N ATUR E O F  O C CUPATI O N
Sedentary Manual Labour
ANOVA
SERUM CRP
(mg/L)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 33.373729 1.00 33.37 11.69 0.00
Within Groups 279.718322 98.00 2.85
Total 313.092051 99.00
Urban; 50Rural; 50
NO  o f  CASES Ac r o s s  TY PE O F  G EO G RAPHY
INTERPRETATION
 The mean of SERUM CRP in  (mg/l) for urban area is 2.62
and 1.47 for rural area.
 The Anova table indicates that the mean level between both
the categories is significantly different.
 The conclusion is that  SERUM CRP is highest  for Urban
area as compared to rural area
Average levels of SERUM CRP across Gender
SERUM CRP (mg/L)
Gender Mean Minimum Maximum No of Cases
Female 1.90 0 5.2 61
Male 2.27 0 5.1 39
Total 2.05 0 5.2 100
Mean
1.90
2.27
SER U M C R P ( mg / l )
M EAN  AC R O SS G EN D ER
Female Male
ANOVA
SERUM CRP
(mg/L)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 3.17 1.00 3.17 1.00 0.32
Within Groups 309.92 98.00 3.16
Total 313.09 99.00
Female; 61
Male; 39
N O o f C AS E S  Acro ss  GE N D E R
INTERPRETATION
 The mean of SERUM CRP (mg/L) for Female Gender is 1.9
and 2.27 for Male Gender .
 The Anova table indicates that the mean level between both
the categories is not significantly different .
 The conclusion is  that  SERUM CRP is not very different
between the gender categories.
Average levels of SERUM CRP across Family History
SERUM CRP (mg/L)
Family History Mean Minimum Maximum No of Cases
Absent 1.37 0 3.7 51
Present 2.74 0 5.2 49
Total 2.05 0 5.2 100
Mean
1.37
2.74
SERUM CRP ( mg / l )
M EAN ACRO SS F AM I LY  H I STO RY  O F  CR P
Absent Present
ANOVA
SERUM CRP
(mg/L)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 46.89 1.00 46.89 17.26 0.00
Within Groups 266.20 98.00 2.72
Total 313.09 99.00
Absent; 51Present; 49
NO  o f  CASES Ac r o s s  F AM I LY  HI STO RY  O F  CRP
INTERPRETATION
 The mean of SERUM CRP in (mg/L) for absent family history
is 1.37 and 2.74 for present family history .
 The Anova table indicates that the mean level between both
the categories is significantly different.
 The conclusion is that SERUM CRP is highest for Present
family history as compared to absent family history.
Average levels of SERUM CRP across BMI
SERUM CRP (mg/L)
BMI Cut off
(Kg/m2) Mean Minimum Maximum No of Cases
<25 0.00 0 0 1
25-29 1.23 0 5.1 32
>=30 2.47 0 5.2 67
Total 2.05 0 5.2 100
Mean
0.00
1.23
SER U M C R P ( mg / l )
M EAN  AC R O SS B M I
<25 25-29 >=30
ANOVA
SERUM CRP
(mg/L)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 37.45 2.00 18.73 6.59 0.00
Within Groups 275.64 97.00 2.84
Total 313.09 99.00
<25; 1
25-29; 32
>=30; 67
N O  o f  CASES Ac r o s s  G EN D ER
INTERPRETATION
 The mean of SERUM CRP in (mg/L) for 25 to 29 BMI cutoff is
1.23 and greater than 30 BMI cutoff is 2.47.
 The Anova table indicates that the mean level between both the
categories is significantly different.
 The conclusion is that SERUM CRP is highest for BMI cutoff
greater than 30 as compared to BMI cutoff for 25 to 29.
Average levels of SERUM CRP across Rural Urban Areas and Gender
SERUM CRP (mg/L)
Area and Gender Mean Minimum Maximum No of Cases
Rural Female 1.49 0 5.20 30
Rural Male 1.44 0 3.90 20
Urban Female 2.30 0 5.10 31
Urban Male 3.15 0 5.10 19
Total 2.05 0 5.20 100
ANOVA
SERUM CRP
(mg/L)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 41.77 3.00 13.92 4.93 0.00
Within Groups 271.32 96.00 2.83
Total 313.09 99.00
Rural Female Rural Male Urban Female Urban Male
1.49 1
2.30
3.15
SERUMCRP (mg/l)
MEAN ACROSS GENDER & GEOGRAPHY
Mean
Multiple Comparisons
SERUMCRP
(mg/L)
Tukey HSD
(I) R_U_SEX (J) R_U_SEX
Mean
Differenc
e (I-J)
Std.
Erro
r
P
Valu
e
95%
Confidenc
e Interval
Lower
Bound
Upper
Boun
d
Rural Male
Urban Male -1.71 0.54 0.01 -3.12 -0.30
Rural Female -0.06 0.49 1.00 -1.32 1.21
Urban Female -0.87 0.48 0.28 -2.13 0.39
Urban Male
Rural Male 1.71 0.54 0.01 0.30 3.12
Rural Female 1.66 0.49 0.01 0.37 2.94
Urban Female 0.84 0.49 0.32 -0.44 2.12
Rural Female
Rural Male 0.06 0.49 1.00 -1.21 1.32
Urban Male -1.66 0.49 0.01 -2.94 -0.37
Urban Female -0.81 0.43 0.24 -1.94 0.31
Urban Female
Rural Male 0.87 0.48 0.28 -0.39 2.13
Urban Male -0.84 0.49 0.32 -2.12 0.44
Rural Female 0.81 0.43 0.24 -0.31 1.94
*. The mean
difference is P
Value significant
at the 0.05 level.
Rural Female; 30
Rural Male; 20
Urban Female; 31
Urban Male; 19
NO of CASES Across GENDER
INTERPRETATION
 The mean of  SERUM CRP  (mg/L)  for  Rural  Female is  1.49,
Rural Male is 1.44,  InUrban Female is 2.30 and Urban Male is
3.15.
 The Anova table indicates that the mean level between one of
the categories are significantly different.
 The multiple comparison tables  indicates that  mean SERUM
CRP is significantly different between Rural Male and Urban
Male and between Urban Male and Rural Female.
 However  between  rural  male  and  rural  female  there  is  no
significant difference between SERUM CRP.
 Also no significance difference between urban male and urban
female there is no significant difference between SERUM CRP.
Average levels of BMI across Rural Urban Areas and Gender
BMI ( Kg/m2)
Area and Gender Mean Minimum Maximum No of Cases
Rural Female 29.27 24.00 40.00 30.00
Rural Male 29.55 26.00 37.00 20.00
Urban Female 32.45 26.00 39.00 31.00
Urban Male 32.89 26.00 38.00 19.00
Total 31.00 24.00 40.00 100.00
ANOVA
BMI ( Kg/m2)
Sum of
Squares df Mean Square F P Value
Between
Groups 265.72 3 88.57 7.63 0.00
Within Groups 1114.28 96 11.61
Total 1380 99
Rural Female Rural Male Urban Female Urban Male
29.27
30
32.45
32.89
BMI ( kg/m2)
MEAN ACROSS GENDER & GEOGRAPHY
Mean
*. The mean difference is P Value significant at the 0.05 level.
Multiple Comparisons
BMI ( Kg/m2 )       
Tukey HSD
(I) R_U_SEX (J) R_U_SEX Mean
Difference
(I-J)
Std.
Error
P
Value
95%
Confidence
Interval  
     
Lower
Bound
Upper
Bound
Rural Male
Urban Male -3.34 1.09 0.01 -6.20 -0.49
Rural Female 0.28 0.98 0.99 -2.29 2.85
Urban Female -2.90 0.98 0.02 -5.46 -0.35
Urban Male
Rural Male 3.34 1.09 0.01 0.49 6.20
Rural Female 3.63 1.00 0.00 1.02 6.24
Urban Female 0.44 0.99 0.97 -2.15 3.04
Rural Female
Rural Male -0.28 0.98 0.99 -2.85 2.29
Urban Male -3.63 1.00 0.00 -6.24 -1.02
Urban Female -3.18 0.87 0.00 -5.47 -0.90
Urban Female
Rural Male 2.90 0.98 0.02 0.35 5.46
Urban Male -0.44 0.99 0.97 -3.04 2.15
Rural Female 3.18 0.87 0.00 0.90 5.47
Rural Female; 30
Rural Male; 20
Urban Female; 31
Urban Male; 19
NO o f  CASES Ac r o s s  G ENDER
INTERPRETATION
 The mean of BMI (Kg/m2) for Rural Female is 29.27, Rural Male
is 29.55, Urban Female is 32.45 and Urban Male is 32.89.
 The Anova table indicates that the mean level between one of
the categories are significantly different .
 The multiple comparison tables indicate that there is significant
difference in BMI levels between urban male and rural male,
also between rural male and urban female.
 Also the mean levels are different between urban female and
rural female.
 Conclusion, mean levels of BMI is highest for urban female as
compared to rural female.
 Mean levels of BMI is highest for urban male as compared to
rural male.
 Mean levels of BMI is highest for urban female as compared to
rural male .
BMI_AGE_Cutoff vs CRP Level
Case Summaries
BMI_AGE_Cutoff
SERUM CRP (ml/L)
Mean Minimum Maximum No of Cases
20 0.00 0.00 0.00 1
22 0.81 0.00 3.90 11
23 1.41 0.00 5.10 15
24 1.53 0.00 4.10 6
32 2.22 0.00 4.80 15
33 2.23 0.00 5.10 35
34 3.16 0.00 5.20 17
Total 2.05 0.00 5.20 100
ANOVA
SERUM CRP
(mg/L)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 51.56 6.00 8.59 3.06 0.01
Within Groups 261.54 93.00 2.81
Total 313.09 99.00
Average levels of SERUMCRP across Gender and Occupation
SERUMCRP (mg/L)
Sex_Occupation Mean Minimum Maximum No of Cases
Female Sedentary 2.11 0.00 5.20 40
Female Manual Labour 1.51 0.00 2.90 21
Male Sedentary 3.14 0.00 5.10 21
Male Manual Labour 1.25 0.00 3.20 18
Total 2.05 0.00 5.20 100
ANOVA
SERUMCRP
(mg/L)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 42.69272957 3.00 14.23 5.05 0.00
Within Groups 270.3993214 96.00 2.82
Total 313.092051 99.00
Female Sedentary Female Manual Labour Male Sedentary Male Manual Labour
2.11
2
3.14
1.25
SERUMCRP (mg/l)
MEAN ACROSS GENDER & OCCUPATION
Mean
INTERPRETATION
 The mean of SERUM CRP (mg/L) is 2.11 for Female Sedentary
occupation,  1.51  for  Female  Manual  Labor,  3.13  for  Male
Sedentary occupation and 1.25 for Male manual labor
 The anova table indicates that there is significant difference in
average SERUM CRP at least between one of the categories
 The  multiple  comparison  table  indicates  that  mean  SERUM
CRP is significantly  different between the following categories
 Female Manual Labour and Male Sedentary occupation
Multiple Comparisons
SERUMCRP
(mg/L)
Tukey HSD
(I)
Sex_Occupatio
n
(J) Sex_Occupation
Mean
Difference
(I-J)
Std.
Erro
r
P
Value
95%
Confidenc
e Interval
Lower
Bound
Upper
Bound
Female
Sedentary
Female Manual 
Labour 0.59 0.45 0.56 -0.59 1.78
Male Sedentary -1.03 0.45 0.11 -2.22 0.15
Male Manual Labour 0.86 0.48 0.28 -0.39 2.10
Female Manual
Labour
Female Sedentary -0.59 0.45 0.56 -1.78 0.59
Male Sedentary -1.63 0.52 0.01 -2.98 -0.27
Male Manual Labour 0.26 0.54 0.96 -1.15 1.67
Male
Sedentary
Female Sedentary 1.03 0.45 0.11 -0.15 2.22
Female Manual 
Labour 1.63 0.52 0.01 0.27 2.98
Male Manual Labour 1.89 0.54 0.00 0.48 3.30
Male Manual
Labour
Female Sedentary -0.86 0.48 0.28 -2.10 0.39
Female Manual 
Labour -0.26 0.54 0.96 -1.67 1.15
Male Sedentary -1.89 0.54 0.00 -3.30 -0.48
*. The mean difference is P Value sinnificant at the 0.05 level.
 Male Sedentary and Male Manual Labour
 Conclusion is that SERUM CRP is highest for Male Sedentary
occupation as compared to Female Sedentary Occupation
 Also, SERUM CRP is highest for Male Sedentary occupation
as compared to Female Sedentary Occupation
BMI Average Across CRP Groups
 BMI (mg/L)
CRP (mg/L) Mean Minimum Maximum No of Cases
NEGATIVE 29.84 24.00 39.00 38.00
POSITIVE(MR) 31.67 26.00 40.00 39.00
POSITIVE(HR) 31.78 25.00 38.00 23.00
Total 31.00 24.00 40.00 100.00
ANOVA
BMI (Kg/m2)
     
 
Sum of
Squares df Mean Square F
P
Value
Between 
Groups 82.37 2 41.18 3.08 0.05
Within Groups 1297.63 97 13.38   
Total 1380 99    
Mean
29.84
31.67
31.78
BM I  M EAN  Ac r o s s  CRP
NEGATIVE POSITIVE(MR) POSITIVE(HR)
Multiple Comparisons
BMI (Kg/m2)
Tukey HSD       
(I) CRP (J) CRP Mean
Difference
(I-J)
Std. Error P
Value
95%
Confidenc
e Interval  
     
Lower
Bound
Upper
Bound
NEGATIVE
POSITIVE(MR
) -1.82 0.83 0.08 -3.81 0.16
POSITIVE(HR
) -1.94 0.97 0.12 -4.24 0.36
POSITIVE(MR
)
NEGATIVE 1.82 0.83 0.08 -0.16 3.81
POSITIVE(HR
) -0.12 0.96 0.99 -2.40 2.17
POSITIVE(HR
)
NEGATIVE 1.94 0.97 0.12 -0.36 4.24
POSITIVE(MR
) 0.12 0.96 0.99 -2.17 2.40
Correlations
  
CRP_Ca
l  
BMI (Kg/m2)
Pearson 
Correlation 0.22  
 
P Value (2-
tailed)
0.03
 
 No of Cases 100  
*. Correlation is P Valuenificant at the 0.05 level (2-
tailed).    
NEGATIVE; 38
POSITIVE(MR); 39
POSITIVE(HR); 23
NO of CASES Across CRP
INTERPRETATION
 The mean of BMI (Kg/m2) for negative CRP is 29.84 and it is
31.67  and  31.78  for  POSITIVE (MR)  and  POSITIVE (HR)
respectively. 
 The ANOVA test indicates that the Average BMI is not highly
significant between the CRP Categories as the P value is 0.51.
 Therefore the conclusion is that BMI levels are not different
between either of the CRP categories.
Triglycerides Average Across Family History
triglycerides
Family_History Mean Minimum Maximum No of Cases
Absent 140.22 121.00 178.00 51
Present 169.35 133.00 189.00 49
Total 154.49 121.00 189.00 100
Mean
140.22
169.35
Tr i g l yc e r i d e s  M e a n  Ac r o s s  F AM I LY  H I STO R Y  o f  C R P
Absent Present
ANOVA
triglycerides
Sum of
Squares df Mean Square F
P
Value
Between
Groups 21207.26051 1 21207.26 100.26 0.00
Within Groups 20729.72949 98 211.53
Total 41936.99 99
Absent; 51Present; 49
NO  o f  CASES Ac r o s s  F AM I LY  H I STO RY  O F  CRP
INTERPRETATION
 The mean of Triglycerides for absent family history is 140.22
and 169.35 for present family history.
 The Anova table indicates that the mean level between both the
categories is highly significantly different.
 The conclusion is  that  the average level  of  Triglycerides for
present family history is significantly higher than absent family
history.
WC Average Across CRP
WC (cm)
CRP (ml/L) Mean Minimum Maximum No of Cases
NEGATIVE 88.34 81.00 103.00 38
POSITIVE(MR) 92.79 78.00 104.00 39
POSITIVE(HR) 103.22 98.00 112.00 23
Total 93.50 78.00 112.00 100
Mean
88.34
92.79
103.22
WAI ST C I R CU M F ER ENC E M e a n  Ac r o s s  CR P( ml / l )
NEGATIVE POSITIVE(MR) POSITIVE(HR)
ANOVA
WC (cm)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 3202.175351 2 1601.09 53.99 0.00
Within Groups 2876.824649 97 29.66
Total 6079 99
Multiple Comparisons
WC (cm)
Tukey HSD
(I) CRP (ml/L) (J) CRP
Mean
Difference
(I-J)
Std.
Erro
r
P
Value
95%
Confidence
Interval
Lower
Bound
Upper
Bound
NEGATIVE POSITIVE(MR) -4.45 1.24 0.00 -7.41 -1.50POSITIVE(HR) -14.88 1.44 0.00 -18.30 -11.45
POSITIVE(MR) NEGATIVE 4.45 1.24 0.00 1.50 7.41POSITIVE(HR) -10.42 1.43 0.00 -13.83 -7.01
POSITIVE(HR) NEGATIVE 14.88 1.44 0.00 11.45 18.30
POSITIVE(MR) 10.42 1.43 0.00 7.01 13.83
*. The mean difference is P Value significant at the 0.05 level.
NEGATIVE; 38
POSITIVE(MR); 39
POSITIVE(HR); 23
N O  o f  C ASES Ac r o s s  C R P
INTERPRETATION
 The average of WC for Negative CRP (mg/L) is 88.34 and 92.79
and  103.22  for  POSITIVE  MR  and  POSITIVE  HR  categories
respectively.
 The Anova table indicates that the mean level between one of the
categories are highly significantly different. 
 The Multiple Comparison tukey test confirms that the average levels
between all three categories are significantly different.
 The  conclusion  is  that  the  average  levels  of  WC are  highest  for
POSITIVE HR CRP, second highest for POSITIVE MR CRP and
Least for NEGATIVE CRP.
HDL Average Across Occupation
HDL (mg/dl)
Occupation Mean Minimum Maximum No of Cases
Sedentary 30.84 21 41 61
Manual Labour 39.18 26 54 39
Total 34.09 21 54 100
Mean
30.84
39.18
H D L M EAN  AC R O SS O CC U PATI O N
Sedentary Manual Labour
ANOVA
HDL(mg/dl)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 1656.085755 1 1656.085755 56.86421728 0.00
Within Groups 2854.104245 98 29.12351271
Total 4510.19 99
Sedentary; 61
Manual Labour; 39
NO  o f  CASES Ac r o s s  NATURE O F  O CCUPATI O N
INTERPRETATION
 The mean of HDL for Sedentary Occupation is 30.84 and 39.18
for Manual Labor.
 The Anova table indicates that the mean level between both the
categories is highly significantly different.
 The conclusion is that the average level of HDL for Manual
Labor is significantly higher than Sedentary Occupation
HDL Average Across Rural and Urban Areas
 HDL (mg/dl)
Rural_Urban_Cal Mean Minimum Maximum No of Cases
Urban 33.04 21 54 50
Rural 35.14 21 45 50
Total 34.09 21 54 100
Mean
33.04
35.14
H DL M EAN AC RO SS G EO G RAPHY
Urban Rural
ANOVA
HDL (mg/dl)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 110.25 1 110.25 2.455601667 0.12
Within Groups 4399.94 98 44.89734694
Total 4510.19 99
Urban; 50Rural; 50
NO  o f  CASES Ac r o s s  TY PE O F  G EO G RAPHY
INTERPRETATION
 The mean of HDL (mg/dl) for Urban area is 33.04 and 35.14 for
Rural Area.
 The Anova table indicates that the mean level between both the
categories is not significantly different.
 The conclusion is that the average level of HDL for Urban area
is not significantly different from rural area.
WC/Height Average Across CRP
WC/HEIGHT
CRP (mg/L) Mean Minimum Maximum No of Cases
NEGATIVE 0.56 0.48 0.65 38
POSITIVE(MR) 0.58 0.47 0.66 39
POSITIVE(HR) 0.65 0.61 0.71 23
Total 0.59 0.47 0.71 100
ANOVA
WC/HEIGHT
(cm)
Sum of
Squares df Mean Square F P Value
Between
Groups 0.119172382 2 0.059586191 37.02864112 0.00
Within Groups 0.156091618 97 0.001609192
Total 0.275264 99
Mean
0.56
0.58
0.65
w c / h e i g h t  ( c m)  me a n  a c r o s s  c r p
NEGATIVE POSITIVE(MR) POSITIVE(HR)
Multiple Comparisons
WC_BY_HEIGHT
(cm)
Tukey HSD
(I) CRP (mg/L) (J) CRP (mg/L)
Mean
Difference
(I-J)
Std.
Erro
r
P
Value
95%
Confidence
Interval
Lower
Bound
Upper
Bound
NEGATIVE POSITIVE(MR) -0.02 0.01 0.04 -0.04 0.00POSITIVE(HR) -0.09 0.01 0.00 -0.12 -0.06
POSITIVE(MR) NEGATIVE 0.02 0.01 0.04 0.00 0.04POSITIVE(HR) -0.07 0.01 0.00 -0.09 -0.04
POSITIVE(HR)
NEGATIVE 0.09 0.01 0.00 0.06 0.12
POSITIVE(MR) 0.07 0.01 0.00 0.04 0.09
* The mean difference is P Value significant at the 0.05 level.
NEGATIVE; 38
POSITIVE(MR); 39
POSITIVE(HR); 23
N O  o f  C ASES Ac r o s s  C R P
INTERPRETATION
 The mean of WC/Height  (cm) for NEGATIVE CRP Level is
0.56, and 0.58 and 0.65 for POSITIVE (MR) and POSITIVE
(HR) respectively.
 The Anova table indicates that the mean level between one of
the three categories are significantly different.
 The multiple comparison tukey tests indicate that mean levels
between all the three categories are significantly different.
 The conclusion is that the mean level of WC/Height is highest
for POSITIVE (HR) CRP, second highest for POSITIVE (MR)
CRP and least for NEGATIVE CRP.
WC Average Across Gender
WC (cm)
Gender Mean Minimum Maximum No of Cases
Female 93.00 81.00 112.00 61
Male 94.28 78.00 106.00 39
Total 93.5 78 112 100
Mean
93.00
94.28
WAI ST CI RCUM F ERENCE M EAN ACRO SS G ENDER
Female Male
ANOVA
WC (cm)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 39.10 1 39.10 0.63 0.43
Within Groups 6039.90 98 61.63
Total 6079 99
Female; 61
Male; 39
NO  o f  CASES Ac r o s s  G ENDER
INTERPRETATION
 The mean of WC (cm)for Female Gender is 93 and for Male
Gender is 94.28.
 The Anova table indicates that the mean level between both the
categories are not significantly different.
 The conclusion is that the average level of WC is not different
between Female and Male and that both are almost the same.
BMI Average Across Gender
BMI
Gender Mean Minimum Maximum No of Cases
Female 30.89 24.00 40.00 61
Male 31.18 26.00 38.00 39
Total 31 24 40 100
Mean
30.89
31.18
WAI ST C I R CU M F ERENCE M EAN ACRO SS G ENDER
Female Male
ANOVA
BMI (Kg/m2)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 2.06 1.00 2.06 0.15 0.70
Within Groups 1377.94 98.00 14.06
Total 1380 99
Female; 61
Male; 39
NO  o f  CASES Ac r o s s  G ENDER
INTERPRETATION
 The mean of BMI (kg/m2 ) for Female Gender is 30.89 and for 
Male Gender is 31.18.
 The Anova table indicates that the mean level between both the
categories is not significantly different.
 The conclusion is that the average level of BMI is not different 
between Female and Male and that both are almost the same.
HDL Average Across Gender
HDL ( mg/dl)
Gender Mean Minimum Maximum No of Cases
Female 36.93 30.00 54.00 61
Male 29.64 21.00 42.00 39
Total 34.09 21 54 100
Mean
36.93
29.64
HDL ( mg / l )  M EAN ACRO SS G ENDER
Female Male
ANOVA
HDL (mg/L)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 1265.48 1.00 1265.48 38.22 0.00
Within Groups 3244.71 98.00 33.11
Total 4510.19 99
Female; 61
Male; 39
N O  o f  CASES Ac r o s s  G ENDER
INTERPRETATION
 The mean of HDL  (mg/L) for Female Gender is 36.93 and for
Male Gender is 29.64.
 The Anova table indicates that the mean level between both the
categories are significantly different.
 The conclusion is that the average level of HDL is highest for
Female and as compared to Male .
WC Average Across Occupation
WC (cm)
Occupation Mean Minimum Maximum No of Cases
Sedentary 97.07 78.00 112.00 61
Manual Labour 87.92 81.00 102.00 39
Total 93.5 78 112 100
Mean
97.07
87.92
W AI ST C I R CU M F ER EN C E M EAN  AC R O SS O CC U PATI O N
Sedentary Manual Labour
ANOVA
WC
Sum of
Squares df Mean Square F
P
Value
Between
Groups 1988.49 1.00 1988.49 47.64 0.00
Within Groups 4090.51 98.00 41.74
Total 6079 99
Sedentary; 61
Manual Labour; 39
NO  o f  CASES Ac r o s s  NATUR E O F  O C CUPATI O N
INTERPRETATION
 The mean of WC (cm) for Sedentary Occupation is 97.07 and
for Manual Labor is 87.92.
 The Anova table indicates that the mean level between both the
categories are significantly different.
 The conclusion is that the average level of  WC is highest for
Sedentary occupation as compared to Manual Labor
. BMI (Kg/m2)  Average Across Occupation
BMI (Kg/m2)  
Occupation Mean Minimum Maximum No of Cases
Sedentary 31.16 24.00 38.00 61
Manual Labour 30.74 26.00 40.00 39
Total 31 24 40 100
Mean
31.16
30.74
B M I   ( k g / m2 )  
M EAN  AC R O SS O C C U PATI O N
Sedentary Manual Labour
ANOVA
BMI (Kg/m2)  
Sum of
Squares df Mean Square F
P
Value
Between
Groups 4.20 1.00 4.20 0.30 0.59
Within Groups 1375.80 98.00 14.04
Total 1380 99
Sedentary; 61
Manual Labour; 39
NO  o f  CASES Ac r o s s  NATURE O F  O CCUPATI O N
INTERPRETATION
 The mean BMI  (Kg/m2)   for Sedentary Occupation is 31.16 and
for Manual Labour is 30.74.
 The Anova table indicates that the mean level between both the
categories are not significantly different .
 The conclusion is that the average level of  BMI is not different
between either of the occupation.
WC (cm) Average Across Age
WC (cm)
Age Mean Minimum Maximum No of Cases
20 - 30 93.04 81.00 106.00 26
31 - 40 92.31 78.00 112.00 51
>40 96.65 82.00 108.00 23
Total 93.50 78.00 112.00 100
ANOVA
WC PValue
Sum of
Squares df Mean Square F 0.08
Between
Groups 305.84 2.00 152.92 2.57
Within Groups 5773.16 97.00 59.52
Total 6079.00 99.00
20 ‐ 30 31 ‐ 40 >40
93.04
92
96.65
WAIST CIRCUMFERENCE (cm)
MEAN ACROSS AGE
Mean
Multiple Comparisons
WC (cm)
Tukey HSD       
(I) Age (J) Age
Mean 
Difference
 (I-J)
Std. Error P Value
95% 
Confidence 
Interval
 
     
Lower
Bound
Upper
Bound
20 - 30 31 - 40 0.72 1.86 0.92 -3.70 5.15
> 40 -3.61 2.21 0.24 -8.87 1.64
31 - 40 20 - 30 -0.72 1.86 0.92 -5.15 3.70
> 40 -4.34 1.94 0.07 -8.95 0.27
> 40 20 - 30 3.61 2.21 0.24 -1.64 8.87
31 - 40 4.34 1.94 0.07 -0.27 8.95
20 - 30; 26
31 - 40; 51
>40; 23
NO  o f  CASES Ac r o s s  AG E
INTERPRETATION
 The mean WC  (cm)  in the age group of 20 to 30 is 93.04, 31
to 40 is 92.31 and greater than 40 is 96.65.
 The Anova table indicates that the mean level between both the
categories are not significantly different
 The conclusion is that the average level of  WC is not different
between the age categories
Average BMI Across Age
BMI ( Kg/m2  )
Age Mean Minimum Maximum No of Cases
20 - 30 30.62 25.00 40.00 26
31 - 40 31.14 24.00 39.00 51
>40 31.13 25.00 38.00 23
Total 31 24 40 100
ANOVA
BMI ( Kg/m2  )
Sum of
Squares df Mean Square F
P
Value
Between
Groups 5.20 2.00 2.60 0.18 0.833
Within Groups 1374.80 97.00 14.17
Total 1380 99
20 ‐ 30 31 ‐ 40 >40
30.62
31 31.13
BMI ( kg/m2  )
MEAN ACROSS AGE
Mea n
Multiple Comparisons
BMI (Kg/m2)
Tukey HSD
(I) Age (J) Age
Mean
Difference 
(I-J)
Std. Error P Value
95%
Confidence
Interval
Lower
Bound
Upper
Bound
20 - 30 31 - 40 -0.52 0.91 0.83 -2.68 1.64> 40 -0.52 1.08 0.88 -3.08 2.05
31 - 40 20 - 30 0.52 0.91 0.83 -1.64 2.68> 40 0.01 0.95 1.00 -2.24 2.26
> 40 20 - 30 0.52 1.08 0.88 -2.05 3.08
31 - 40 -0.01 0.95 1.00 -2.26 2.24
20 - 30; 26
31 - 40; 51
>40; 23
NO  o f  CASES Ac r o s s  AG E
INTERPRETATION
 The mean BMI ( Kg/m2  ) in the age category of 20 to 30 is 30.62
and  31.14  and  31.13  for  31  to  40  and  greater  than  40
respectively.
 The Anova table indicates that the mean level between both the
categories are not significantly different .
 The conclusion is that the average level of  BMI is not different
between the age categories .
Average HDL Across Age
HDL (mg/dl)
Age Mean Minimum Maximum No of Cases
20 - 30 33.46 21.00 44.00 26
31 - 40 35.49 21.00 54.00 51
>40 31.70 21.00 45.00 23
Total 34.09 21 54 100
ANOVA
HDL (mg/dl)
Sum of
Squares df Mean Square F
P
Value
Between
Groups 242.11 2.00 121.06 2.75 0.07
Within Groups 4268.08 97.00 44.00
Total 4510.19 99.00
20 ‐ 30 31 ‐ 40 >40
33.46
35
31.70
HDL (mg/dl) 
MEAN ACROSS AGE
Mean
Multiple Comparisons
HDL (mg/dl)
Tukey HSD
(I)
Age_Cutoff
(J)
Age_Cutoff
Mean
Difference
(I-J)
Std. Error P Value
95%
Confidenc
e Interval
Lower
Bound
Upper
Bound
20 - 30 31 - 40 -2.03 1.60 0.42 -5.83 1.78> 40 1.77 1.90 0.62 -2.75 6.29
31 - 40 20 - 30 2.03 1.60 0.42 -1.78 5.83> 40 3.79 1.67 0.06 -0.17 7.76
> 40 20 - 30 -1.77 1.90 0.62 -6.29 2.75
31 - 40 -3.79 1.67 0.06 -7.76 0.17
20 - 30; 26
31 - 40; 51
>40; 23
NO  o f  CASES Ac r o s s  AG E
INTERPRETATION
 The mean HDL (mg/dl)  in the age category of 20 to 30 is 33.46
and  35.49  and  31.70  for  31  to  40  and  greater  than  40
respectively.
  The Anova table indicates that the mean level between both
the categories is not significantly different.
 The conclusion is that the average level of HDL is not different
between the age categories .

DISCUSSION 
DISCUSSION
Obesity  is  a  chronic  inflammatory  disorder  which  is  associated
with increase cardio metabolic morbidity and mortality.
It is defined with various anthropometric measurements like body
mass index (BMI), weight circumference, waist height ratio and etc.
 In obese population dysfunctional adipocyte was associated with
increase  level  of  inflammatory  markers.  This  marker  indicates  future
outcome  of  obesity  related  disorders.  In  our  study  serum  C-reactive
protein  is  taken as  an  inflammatory marker.  In  our  present  study 100
sample population was taken. CRP level less than 1 mg/l was taken as
CRP negative. More than 1 mg/l was positive. In hundred patients, 62
persons are having CRP level more than 1 mg/l.
In our study, the mean of SERUM CRP for 25Kg/m2 to 29Kg/m2
BMI cutoff is 1.23 and greater than 30 BMI cutoff is 2.47. The SERUM
CRP is highest for BMI cutoff greater than 30 as compared to BMI cutoff
for 25 to 29.
 In present study the mean of BMI for Rural Female is 29.27, Rural
Male is 29.55, Urban Female is 32.45 and Urban Male is 32.89.  Mean
levels of BMI is highest for urban female as compared to rural female.
Mean levels of BMI is highest for urban male as compared to rural male.
Mean levels of  BMI is highest for urban female as compared to rural
male. Ghosh A  62 study states that obesity prevalence not affected with
particular  residence.  Study  by  Shah  Ebrahim  63 states  that  in  Urban
Migration population Obesity rate was high.
The mean of SERUM CRP for Urban area is 2.62 and 1.47 for
rural area. The SERUM CRP is highest for urban area as compared to
rural area.
In  our  study  the  mean  of  SERUM  CRP  is  2.11  for  Female
Sedentary  occupation,  1.51  for  Female  Manual  Labor,  3.13  for  Male
Sedentary occupation and 1.25 for  Male manual  labor.  Also,  SERUM
CRP is highest for Male Sedentary occupation as compared to Female
Sedentary Occupation. Choi. J  et al study also shows that increase level
of CRP is stronger in female than male. 
In our study, the mean of SERUM CRP for Rural Female is 1.49,
Rural  Male  is  1.44,  Urban  Female  is  2.30  and  Urban  Male  is  3.15.
However  between  rural  male  and  rural  female  there  is  no  significant
difference  between  SERUM  CRP.  Also  no  significance  difference
between urban male and urban female there is no significant difference
between SERUM CRP.
The  average  of  WC for  Negative  CRP is  88.34  and  92.79  and
103.22 for POSITIVE MR and POSITIVE HR categories respectively.
The  conclusion  is  that  the  average  levels  of  WC  are  highest  for
POSITIVE HR CRP, second highest for POSITIVE MR CRP and Least
for  NEGATIVE CRP.  Increase  in  waist  circumference  was  associated
with increase CRP level. It is an important predictor to access the rick for
IHD and DM.
In the article  of Hirofumi Nakamura 64 and Emanuela Lapice  65,
studies states that Waist circumference is the main determinant in obesity
to identify high risk group. It is independent of BMI. In our study also
increase  Waist  circumference  in  more  than 90cm was  associated  with
increase CRP level. 
The mean of WC for Female Gender is 93 and for Male Gender is
94.28. The average level  of  WC is not  different  between Female and
Male and that both are almost the same. The  mean  of  WC  for
Sedentary Occupation is 97.07 and for Manual Labor is 87.92 .  The
average level of WC is highest for sedentary occupation as compared to
Manual Labor. 
The mean of WC/Height for NEGATIVE CRP Level is 0.56, and
0.58 and 0.65 for POSITIVE (MR) and POSITIVE (HR) respectively.
The  mean  level  of  WC/Height  is  highest  for  POSITIVE  (HR)  CRP,
second highest for POSITIVE (MR) CRP and least for NEGATIVE CRP.
Waist  height  ratio  also  very  important  measurement  to  predict  cardio
metabolic risk in obese people. 
The mean of SERUM CRP for absent family history is 1.37 and
2.74 for present family history.  The SERUM CRP is highest for positive
family history as compared to absent family history. In the article of
CDC features study on Obesity & Genetics and Lisa Y Gibson 66 studies
states that no clear evidence for family history and obesity. But it also
states  that  not  only genetic  influence,  environmental  factor  the  family
member  shared,  eating  habits,  and  physical  inactivity  influence  the
obesity of the particular person. In our study family style is a significance
impact on obesity.
The mean of SERUM CRP for sedentary occupation is 2.46 and
1.39  for  manual  labor.  The  SERUM  CRP  is  highest  for  Sedentary
Occupation as compared to manual labor occupation.
The mean of SERUM CRP for Female Gender is 1.9 and 2.27 for
Male Gender. The conclusion is that SERUM CRP is not very different
between the gender categories.
SUMMARY
SUMMARY
In our study the SERUM CRP is highest for BMI cutoff greater
than 30 as compared to BMI cutoff for 25Kg/m2 to 29Kg/m2 
Mean levels of BMI is highest for urban female as compared to
rural female. 
Mean levels of BMI is highest for urban male as compared to rural
male. 
Mean levels of BMI is highest for urban female as compared to
rural male.
No significant difference between SERUM CRP of rural male and
rural female, urban male and urban female.
The SERUM CRP is highest for urban area as compared to rural
area.
SERUM  CRP  is  highest  for  Male  Sedentary  occupation  as
compared to Female Sedentary Occupation .
The average levels of WC are highest for POSITIVE (HR) CRP,
second  highest  for  POSITIVE  (MR)  CRP  and  Least  for
NEGATIVE CRP.
In our study increase waist circumference in more than 90cm was
associated with increase CRP level.
The average level of WC is highest for sedentary occupation as
compared to Manual Labor.
The mean level of WC/Height is highest for POSITIVE (HR) CRP,
Second highest for POSITIVE (MR) CRP and least for NEGATIVE 
CRP. 
The  SERUM  CRP  is  highest  for  positive  family  history  as
compared to absent family history.
The conclusion is that SERUM CRP is not very different between
the gender categories.
CONCLUSION
CONCLUSION
Obesity is a slowly progressive inflammation Serum CPR level is
most powerful marker for Cardio metabolic risk. Abdominal obesity was
associated with high level of Serum CRP. Early life style modification
like regular physical exercise and avoiding high calorie diet will help to
improve   the quality of life, Family members also to be included in the
life  style  modification.  Statin  has  both  lipid  lowering  effect  and  Anti
inflammatory effect.  The use of Statin in obese person with normal lipid
profile with elevated CRP level can be evaluated by further studies. 

PROFORMA 
PROFORMA
Serial No :
Patient information   
Name :                                                  Patient No :                           
Income :                                                
Age :                          Sex :                       Address:
Occupation :                                             Menstrual history :
Past History 
Diabetes                     : 
Hypertension             :
Past drug History      :
Cardiac disease         :
Associated illness     :
Family History : 
General physical examination 
Pulse  :                  Pallor :                  Emaciation :                  Pedal edema
:
BP      :                 Icterus :                 Oral thrush :                   Facial 
puffiness:
RR      :                 Cyanosis :               Clubbing :                 
Lymphadenopathy:
Temp  :               Weight in Kg:     Height in cm:   Waist 
circumference in cm : 
CVS    :
RS      :
PA      :
CNS   :
INVESTIGATIONS 
Blood sugar :
Lipid Profile :
Serum C-reactive Protein :

CONSENT FORM 
CONSENT  FORM
Yourself   Mr./Mrs./Ms. ……………………………………  are   being
asked   to   be  a  participant  in  the  research  study  titled  “A STUDY
ON SERUM C-REACTIVE PROTEIN LEVEL IN OBESITY“  in  CMC
hospital,  Coimbatore  ,  conducted   by   Dr.  T.  Dhanalakshmi,  Post
Graduate   Student,  Department    of   General   Medicine,  Coimbatore
Medical  College.  You  are  eligible  after  looking  into  the  inclusion
criteria  .You  can  ask  any  question  which  you  may  have  before
agreeing  to  participate.  
Research  Being  Done 
A STUDY ON SERUM C-REACTIVE PROTEIN LEVEL IN OBESITY
Purpose  of  Research 
 To test whether overweight and obesity are associated with 
low-grade systemic inflammation as measured by serum C-
reactive protein (CRP) level.  
 To study the c reactive protein level in obesity using 
measures of body mass index. 
 To study CRP level in obese women and men.
Decline  from  Participation
You  have  the  option  to  decline  from  participation  in  the  study
existing  protocol  for  your  condition.
Privacy  and  Confidentiality
Privacy  of  individuals  will  be  respected  and  any  information  about
you  or  provided  by  you  during  the  study  will  be  kept  strictly
confidential.
Authorization  to  publish  Results 
Results  of  the  study  may  be  published  for  scientific  purposes
and/or  presented  to scientific  groups,  however  you  will  not  be
identified.
Statement  of  Consent 
I   volunteer   and consent to participate   in   this study.  I have read the
consent   or   it   has   been   read   to me. The   study   has   been  fully
explained  to   me,  and   I  may  questions   at  any  time.
……………………………….                                             
………………………...
Signature/Left thumb impression                                                        Date 
          (Volunteer)
………………………………….                                        
…………………………
Signature   of   witness                                                                           
Date
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Gene Gene Product Mechanism of Obesity In Human In Rodent
Lep (ob) Leptin, a fat-derived hormone Mutation prevents leptin from delivering satiety signal; brian perceives starvation Yes Yes
LepR (db) Leptin receptor Same as above Yes Yes
POMC Proopiomelanocortin, a precursor of several hormones and neuropeptides
Mutation prevents synthesis of melanocyte-
stimulating hormone (MSH), a satiety signal Yes Yes
MC4R Type 4 receptor for MSH Mutation prevents reception of satiety signal from MSH Yes Yes
AgRP Agouti-related peptide, a neuropeptide expressed in the hypothalamus Overexpression inhibits signal through MC4R No Yes
PC-1 Prohormone convertase 1, a processingenzyme
Mutation prevents synthesis of neuropeptide, 
probably MSH Yes No
Fat Carboxypeptidase E, a processing enzyme Same as above No Yes
Tub Tub, a hypothalamic protein of unknown function Hypothalamic dysfunction No Yes
TrkB TrkB, a neurotrophin receptor Hyperphagia due to uncharacterized hypothalamic defect Yes Yes
Table 2. Some Obesity Genes in Humans and Mice
Table 3. A Comparison of Syndrome of Obesity-Hypogonadism and Mental Retardation
Feature
Syndrome
Prader-Willi Laurence-Moon-Biedl Ahlstrom’s Cohen’s Carpenter’s
Inheritance Sporadic; two-thirds have defects Autosomal recessive Autosomal recessive
Probably autosomal 
recessive
Autosomal 
recessive
Stature Short Normal; infrequently short
Normal; infrequently 
short Short or tall Normal
Obesity
Generalized Generalized Truncal Truncal Truncal, gluteal
Moderate to severe Early onset, 1-2 years Early onset, 1-2 years Mid-chidhood, age 5
Onset 1-3 years
Craniofacies
Narrow bifrontal diameter Not distinctive Not distinctive High nasal bridge Acrocephaly
Almond-shaped eyes Arched palate Flat nasal bridge
Strabismus Open mouth High-arched palate
V-shaped mouth Short philtrum
High-arched palate
Limbs
Small hands and feet Polydactyly No abnormalities Hypotonia Polydactyly
Hypotonia Narrow hands and feet Syndactyly
Genu valgum
Reproductive
status 1º Hypogonadism 1º Hypogonadism
Hypogonadism in 
males but not in 
females
Normal gonadal function 
or hypogonadotrophic 
hypogonadism
2º Hypogonadism
Other 
features
Enamel hypoplasia Dysplastic ears
Hyperphagia Delayed puberty
Temper tantrums
Nasal speech
Mental 
retardation Mild to moderate Normal intelligence Mild Slight
Thesis Title  : A STUDY ON SERUM C-REACTIVE PROTEIN LEVEL IN OBESITY
S.No OP No Name Age (Yrs) Sex Weight (Kg) Height (cm) Ht (m) BMI WC Triglycerides HDL
1 50320 Ganesh 30 M 81 176 1.76 26 89 1.8 140 36 Manua R
2 50544 Kumar 41 M 71 159 1.59 28 98 2.2 123 32 Manua R
3 51567 Veeran 40 M 78 164 1.64 29 88 2.6 168 30 sedent R Present
4 51346 Vimalan 36 M 72 160 1.60 28 102 3.8 175 24 sedent R Present
5 52888 Murugan 30 M 77 166 1.66 28 88 2.1 134 37 Manua R
6 52899 Nandhu 32 M 73 167 1.67 26 89 1.9 141 40 Manua R
7 53012 Kalimuthu 29 M 82 171 1.71 28 106 3.9 167 24 sedent R Present
8 53120 Kabilan 40 M 78 164 1.64 29 104 3.7 156 21 sedent R Present
9 53155 Rajan 30 M 83 164 1.64 31 99 2.9 176 26 sedent R Present
10 53179 Maruthamuthu 36 M 92 160 1.60 36 104 3.8 159 26 sedent R Present
11 53226 Maran 42 M 86 169 1.69 30 98 4.1 186 25 sedent U Present
12 53477 Cheran 38 M 92 175 1.75 30 95 3.7 183 26 sedent U Present
13 53568 Raman 22 M 85 158 1.58 34 102 3.8 169 25 sedent U Present
14 53678 Ezhil Muthalvan 38 M 90 165 1.65 33 78 3.97 189 22 sedent U Present
15 54234 Balu 32 M 92 172 1.72 31 98 2.6 125 38 Manua U
16 54321 Vasanth 30 M 84 162 1.62 32 93 3.5 143 21 sedent U
17 54456 Kannan 42 M 87 158 1.58 35 104 3.7 132 24 sedent U
18 54789 Chinnasamy 40 M 90 160 1.60 35 102 3.1 126 35 Manua U
19 54880 Raja 42 M 82 163 1.63 31 90 3.2 133 42 Manua U Present
20 55000 Rajappan 40 M 81 159 1.59 32 89 2.8 122 37 Manua U
21 55057 Ghunasekaran 40 M 96 163 1.63 36 103 4.2 179 23 sedent U Present
22 55109 Kesavan 40 M 96 159 1.59 38 102 5.1 182 22 sedent U Present
23 55167 Rasu 25 M 97 174 1.74 32 106 4.3 185 21 sedent U Present
24 55198 Dharman 24 M 96 173 1.73 32 88 2.8 137 35 Manua U
25 55220 Maran 32 M 95 165 1.65 35 104 4.1 176 25 sedent U Present
26 55255 Gurusamy 36 M 90 165 1.65 33 102 4.8 171 24 sedent U Present
27 55289 Raja 30 M 73 167 1.67 26 103 <1 165 24 sedent U Present
28 55358 Narayanasamy 40 M 83 175 1.75 27 86 <1 135 32 Manua R Present
29 55398 Rajamani 20 M 75 164 1.64 28 89 <1 167 26 Manua R Present
30 55410 Karuppusamy 25 M 69 163 1.63 26 81 <1 132 35 Manua R
SERUM 
CRP 
LEVEL      
(mg/l)
OccupaƟ
Ɵon
Rural/U
rban
Family 
History
31 55433 Mathavan 25 M 76 168 1.68 27 84 <1 138 38 Manua R
32 55477 Selvaraj 30 M 87 165 1.65 32 89 <1 165 25 sedent R
33 55490 Rajarajan 38 M 96 168 1.68 34 81 <1 131 39 Manua R
34 55523 Muthusamy 42 M 88 159 1.59 35 101 <1 169 21 sedent U Present
35 55589 Sivakumar 38 M 98 163 1.63 37 88 <1 130 40 Manua R
36 55610 Senthil 38 M 96 163 1.63 36 89 <1 136 39 Manua R
37 55689 Ravi 29 M 94 164 1.64 35 92 <1 165 23 sedent U Present
38 55723 Chandran 38 M 73 164 1.64 27 88 <1 134 37 Manua R
39 55756 Selvarasu 29 M 88 177 1.77 28 85 <1 133 36 Manua R
40 55822 Kaliswari 26 F 83 156 1.56 34 86 2.3 186 41 Manua R Present
41 55845 Malliga 30 F 79 157 1.57 32 84 2.5 177 43 Manua R Present
42 55878 Dhaiva 28 F 97 156 1.56 40 89 2.6 140 40 Manua R
43 55911 Chandra 28 F 85 158 1.58 34 101 2.7 134 32 sedent R
44 55912 Kamalammal 33 F 87 162 1.62 33 82 2.1 138 40 Manua R
45 56001 Kavitha 29 F 85 163 1.63 32 102 3.7 162 32 sedent R Present
46 56053 Murugathal 36 F 87 153 1.53 37 102 3.8 165 36 sedent R Present
47 56121 Narmatha 32 F 73 153 1.53 31 89 2.1 136 44 Manua R
48 56145 Rathiga 40 F 75 153 1.53 32 101 5.2 173 36 sedent R Present
49 56189 Noornisha 36 F 61 156 1.56 25 104 3.9 170 41 sedent R Present
50 56221 Lakshmiammal 32 F 82 158 1.58 33 85 2.9 166 40 Manua R Present
51 56256 Padma 33 F 81 154 1.54 34 89 2.8 131 43 Manua R
52 56290 Menaga 30 F 66 159 1.59 26 88 2.6 133 41 Manua R Present
53 56311 Rajeshwari 40 F 67 158 1.58 27 89 2.9 136 45 Manua R
54 56329 Rajammal 25 F 61 153 1.53 26 89 2.6 138 44 Manua R
55 56377 Marriammal 25 F 76 154 1.54 32 100 4.2 182 35 sedent U Present
56 56390 Sasikala 28 F 74 160 1.6 29 99 4.8 164 40 Sedent U Present
57 56456 Saraswathy 30 F 67 158 1.58 27 102 5.1 140 37 sedent U Present
58 56478 Indhira 35 F 89 157 1.57 36 98 2.2 175 52 Manua U Present
59 56199 Susi 40 F 81 159 1.59 32 102 4.9 168 33 sedent U Present
60 56505 Maruthal 32 F 83 159 1.59 33 103 2.8 169 35 sedent U
61 56589 Essakki 26 F 91 159 1.59 36 92 2.1 178 44 Manua U
62 56612 Dhanya 42 F 64 157 1.57 26 105 4.1 162 36 sedent U Present
63 56619 Lakshmi 43 F 92 156 1.56 38 98 2.9 171 34 Sedent U
64 56687 Meena 38 F 78 159 1.59 31 99 2.7 132 35 Sedent U
65 56723 Sridevi 33 F 90 163 1.63 34 104 4.8 173 36 sedent U Present
66 56756 Ananthammal 34 F 87 158 1.58 35 112 5.1 167 38 sedent U Present
67 56790 Suganya 40 F 71 156 1.56 29 108 4.9 162 36 sedent U Present
68 56811 Latha 38 F 76 157 1.57 31 98 2.1 178 54 Manua U Present
69 56834 Maral 38 F 69 149 1.49 31 98 2.5 131 36 Sedent U
70 56899 Rafia 40 F 76 154 1.54 32 98 3.4 169 35 sedent U Present
71 56900 Ponnammal 34 F 91 161 1.61 35 93 2.2 130 34 Sedent U
72 57023 Shifa 32 F 86 157 1.57 35 94 2.7 136 41 sedent U
73 57122 Kannaki 32 F 83 159 1.59 33 103 2.9 134 36 sedent U
74 57156 Monisha 28 F 72 160 1.6 28 92 2.4 138 37 sedent U
75 57289 Sherine 32 F 71 156 1.56 29 94 2.6 135 32 sedent U
76 57390 Ponni 28 F 78 159 1.59 31 96 <1 176 34 edentar U PRESENT
77 57412 Mariyammal 29 F 90 160 1.6 35 94 <1 179 35 edentar U PRESENT
78 57434 Kaliammal 42 F 79 157 1.57 32 82 <1 172 31 edentar U PRESENT
79 57456 Kuppammal 34 F 87 149 1.49 39 85 <1 125 39 nual Lab U
80 57678 Indhirani 37 F 78 159 1.59 31 84 <1 121 37 nual Lab U
81 57699 Mangalm 39 F 77 153 1.53 33 81 <1 178 32 edentar U PRESENT
82 57789 Bhuvaneshwari 38 F 78 151 1.51 34 83 <1 125 38 nual Lab U
83 57890 Mahalakshmi 30 F 73 149 1.49 33 88 <1 173 33 edentar U PRESENT
84 57920 Fathima 28 F 85 158 1.58 34 90 <1 166 31 edentar U
85 58109 Rafiabeham 24 F 79 157 1.57 32 86 <1 169 33 edentar U
86 58120 Nithya 36 F 66 156 1.56 27 92 <1 164 31 edentar R
87 58234 Jayamarie 42 F 70 158 1.58 28 94 <1 168 30 edentar R
88 58345 Kamalambal 39 F 71 159 1.59 28 92 <1 171 33 edentar R PRESENT
89 58467 Mariya 22 F 64 157 1.57 26 92 <1 165 31 edentar R
90 58567 Roshini 32 F 68 159 1.59 27 84 <1 123 41 nual Lab R
91 58690 Valli 28 F 66 156 1.56 27 88 <1 166 32 edentar R
92 58745 Mailathal 30 F 49 143 1.43 24 86 <1 173 35 edentar R PRESENT
93 58934 Meenachi 32 F 63 156 1.56 26 84 <1 126 37 nual Lab R
94 59034 maheswari 32 F 76 162 1.62 29 83 <1 128 36 nual Lab R
95 59167 Ranjini 36 F 54 142 1.42 27 83 <1 123 40 nual Lab R
96 59256 Aandal 37 F 69 157 1.57 28 83 <1 126 35 nual Lab R
97 59321 Latha 40 F 59 153 1.53 25 89 <1 165 35 edentar R
98 59432 Baby 40 F 79 162 1.62 30 92 <1 172 34 edentar R PRESENT
99 59576 Devi 21 F 63 159 1.59 25 88 <1 177 32 edentar R PRESENT
100 60123 Nalini 24 F 61 156 1.56 25 102 <1 162 34 edentar R
WC‐ waist circumference   or   Circumference of Waist 
BMI ‐ Body Mass Index (kg/m2)
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